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Thirteen percent of South Africans are living with HIV and of those infected, 52% are on antiretroviral 
therapy (ART). ART has changed the course of this terminal illness to one of a chronic illness. However, 
the longer life span of people living with HIV has brought about numerous metabolic disorders 
particularly with change in cholesterol metabolism and risk of cardiovascular disease. Gallstone disease 
(GD) is also known to be triggered by cholesterol metabolism changes; thus, it is postulated that people 
living with HIV and ART may be at risk for developing gallstones as well. In South Africa (SA), there 
is evidence of an increase incidence of GD in black South Africans, a disease once with a low incidence 
amongst this population group which makes up over 80% of the country’s population. GD also ranks 
as one of the world’s most expensive disorders to health care systems and thus investigating a causative 
relationship between HIV, ART and GD has relevance to reduce the burden on our already constrained 
health care system in SA.   
Aim  
The aim of this study was to determine differences in clinical profiles and regulators of hepatic 
cholesterol and bile acid metabolism in HIV+ve Black South African women on ART presenting with 
gallstones compared to HIV-ve Black South African women with gallstones.  
Methods 
A case series study was conducted amongst all Black South African women undergoing 
cholecystectomy for gallstone disease over a 1-year period at King Edward VIII Hospital, Durban, SA. 
A total of 52 patients (34 HIV-ve and 18 HIV+ve) were assessed. Classical risk profiles (age, BMI, 
children, family history) and lipogram levels. (LDL-c, HDL-c, triglycerides, total cholesterol) were 
compared between the HIV+ve and HIV-ve women.  Categorical variables were tested using either the 
Fisher’s exact test or Pearson’s Chi-square test. Means were compared using independent t-tests. For 
non-normally distributed data, the Mann-Whitney test was used. Statistical tests were two-sided, and p 
values of less than 0.05 were considered as statistically significant. Liver biopsies from five HIV+ve 
women and five HIV-ve women were analyzed for hepatic expression of key genes in cholesterol 
metabolism (LDLr, HMGCR, ABCA1) and transcriptional regulators of these genes (microRNA-148a, 
SREBP2) using quantitative PCR. The same five HIV+ve and five HIV-ve women were evaluated for 
gene expression of CYP7A1, HNF1α, HNF4α, LXRb, miR-194-5p and miR-122*_1 using RT-qPCR. 
Messenger RNA and miRNA levels were reported as fold change expressed as 2-ΔΔCt (RQ min; RQ 




The median age of HIV+ve vs HIV-ve women was 35 years and 50 years respectively (p=0.015). The 
HIV-ve group had a statistically significant number of patients in the overweight/obese category (BMI 
> 25kg/m2) compared to the normal weight category (BMI <25kg/m2) (p<0.001). The number of obese 
women in the HIV+ve group however did not reach statistical significance.  Circulating total cholesterol 
was elevated in the HIV+ve group with significantly elevated LDL-c levels (3.16±0.64mmol/L) relative 
to uninfected women (2.10±0.74mmol/L; p=0.04). A scavenging receptor for LDL-c, LDLr was 
significantly decreased (0.18-fold) in this group, possibly contributing to higher LDL-c levels. 
Transcriptional regulator of LDLr, SREBP2 was also significantly lower (0.13-fold) in HIV+ve women. 
Regulatory microRNA, miR-148a-3p, was reduced in HIV+ve women (0.39-fold) with a concomitant 
increase in target ABCA1 (1.5-fold), which regulates cholesterol efflux.  HIV+ve women displayed 
higher CYP7A1 [2.078-fold (RQ min: 1.278; RQ max: 3.381)], LXRb [2.595-fold (RQ min: 2.001; RQ 
max: 3.000)] and HNF1α [3.428 (RQ min: 1.806; RQ max: 6.507] levels. HNF4α [0.642-fold (RQ min: 
0.266; RQ max: 1.55)], miR-194-5p [0.527-fold (RQ min: 0.37; RQ max: 0.752)] and miR-122*_1 
[0.595-fold (RQ min: 0.332; RQ max: 1.066)] levels were lower in HIV-ve women. 
Conclusion 
HIV+ve women do not conform entirely to the normal known risk profile for GD.  Black South African 
HIV+ve women with GD were significantly younger. Black South African HIV-ve women conform to 
the known risk factor of obesity with a statistically higher BMI whilst HIV+ve women do not.  HIV+ve 
women also had fewer 1st degree relatives with GD compared to HIV-ve women, and less oestrogen 
exposure. HIV+ve women have a significant increase in circulating LDL-c coupled with reduced 
mRNA expression of hepatic LDLr. However, the suppression of miR-148, an epigenetic regulator of 
LDLr, was downregulated in the HIV+ve group. This would indicate a possible alternate pathway in 
the downregulation of LDLr in HIV+ve women linked with raised LDL-c and gallstone formation and 
will require further investigation. MiR-148a however did appear to regulate ABCA1 with an inverse 
relationship being observed in the HIV+ve woman. HIV+ve women displayed elevated expression of 
CYP7A1, HNF1α and LXRb. This could have been further influenced by ART and aging. HNF4α, 
which is known to cause upregulation of CYP7A1, was suppressed with upregulation of CYP7A1 and 
LXR, known to cause downregulation of CYP7A1 in humans as opposed to mice, also had the opposite 
effect in HIV+ve women. The best theoretical explanation for this will be an interruption in the 
enterohepatic circulation, as evident by HIV+ve patients known to have chronic inflammatory and 
relative malabsorptive disorders of the ileum, which may result in upregulation of CYP7A1 to produce 
more bile salts. However, these conclusions are drawn from a case series. Larger cohort studies are 
required into the effects of HIV on GD and the impact of ART on GD in order to put strategies in place 




CHAPTER 1: INTRODUCTION 
1.1 Background 
South Africa has a population of 57.7 million and it is estimated that 7.52 million (13,1%) are living 
with Human Immune deficiency virus (HIV), the highest than any other country (1). Almost 26% of 
the infected reside in the province of KwaZulu Natal (1). Of those infected, 3.9 million patients (52%) 
are on antiretroviral therapy (ART) (1).  
The introduction of ART to treat HIV has changed a previously terminal illness to a chronic, 
manageable disease. This extended life span has seen an unprecedented number of patients living longer 
with HIV – this has seen the development of adverse outcomes resembling metabolic syndrome 
(hypertriglyceridemia, low high-density lipoprotein cholesterol, and insulin resistance), which increases 
risk for cardiovascular disease (CVD) (2). The pathology for this metabolic syndrome varies, but it is 
thought that the pathology in HIV positive (+ve) patients differ from HIV negative (-ve) patients as 
classical characteristics e.g.  increased waist circumference occurs less frequently. The host response to 
HIV infection, specific ARTs, mitochondrial toxicity, and HIV-associated altered fat metabolism are 
factors contributing to these metabolic outcomes.  As health is restored, those that are genetically 
predisposed, will manifest with metabolic syndrome. The vulnerability to higher incidences of CVD in 
the absence of known risk factors such as smoking in these HIV+ve patients is thus higher (2).  
The pathogenesis of gallstone disease (GD) is well established in HIV-ve patients. However, unlike 
metabolic syndrome specific to HIV, gallstones specific to HIV has not been studied. Gallstone 
formation occurs due to supersaturation of cholesterol in bile, and this supersaturation has been 
attributed to risks commonly referred to the five “F”s (Female, Fat, Fertile, Forty and Family history) 
(3). The observed metabolic changes in HIV+ve patients may contribute to GD, as these patients are 
known to have increased circulating lipid levels. The evidence for this is that lipid levels rise 
concomitantly with HIV RNA levels independent of ART. Further, ART use increases lipid release into 
the bloodstream, thus both resulting in hyperlipidemia (4). This may in turn make HIV+ve patients 
vulnerable to higher incidences of GD without known risk factors such as the 5 “F’s, however this has 








1.2 Problem Statement 
The incidence of gallstones in Sub-Saharan Africans is reportedly one of the lowest in the world, to the 
extent of being labeled as “almost non-existent in the Bantu population of sub Saharan Africa” (5), 
compared to the rest of the developed world where the incidence averages about 20% (6). These clinical 
observations were made in small sample sizes and date back more than 30 years (7). However in a 
recent study by Khan et al (2020) (8) studying cholecystectomies in public sector hospitals in South 
Africa accounting for 82% of the country’s population which makes up 87% Black Africans (1) they 
showed an increase of cholecystectomies by 65% between the years 2004 to 2014 (8).  The anecdotal 
evidence of increasing prevalence in recent times, especially in Black Africans is mostly attributed to 
urbanization together with urbanized diets and increasing obesity particularly amongst black African 
women (9) . As Khan’s study (2020) was only a review of cholecystectomy specimens, HIV results 
were thus lacking and no link or relation to the increase of HIV during those years of study could be 
drawn. GD and its complications (cholecystitis, biliary colic, gallstone pancreatitis, gallbladder cancer, 
and obstructive jaundice) are treated by surgical intervention, making it one of the world’s most 
expensive diseases (10). As a result, this places a huge economic burden and immense pressure on the 
already resource constrained health care system in South Africa especially with recent evidence 
mounting to an almost doubling cholecystectomy rate in the last decade (8). This rise in gallstone 
incidence is paralleled with the rise in incidence of HIV and the judicious role out of ART. HIV and 
ART drugs are known to affect cholesterol homeostasis, however the effect on gallstone formation has 
not been studied. Detection of modifiable risk factors for gallstone formation specific to our population 
especially linked to the recent rise in incidence is crucial in South Africa in the era of HIV and ART. 
This will provide evidence to guide healthy policy makers and implementers of health interventions on 
the most appropriate intervention for reducing gallstones and the complications associated with it to 
reduce the high disease burden on our resource constrained health care system in South Africa. Further, 
the identification of molecular mechanisms of pathology allow investigation into targeted intervention 










The main hypothesis is HIV+ve women on ART display different risk factors and pathological profiles 
to HIV-ve women presenting with gallstone disease. 
 
1.4 Research Questions 
1.4.1 Main research question 
Are there differences in the pathophysiology and risk factors of gallstone development amongst HIV 
+ve and HIV-ve black South African women? 
1.4.2 Specific research questions 
1. Are there differences in clinical, biochemical and demographic parameters between HIV+ve 
and HIV-ve women presenting with gallstones?  
2. Are genetic and epigenetic regulators of hepatic cholesterol metabolism differentially regulated 
in HIV+ve women presenting with gallstones compared to HIV-ve women? 
3. Are genetic and epigenetic regulators of hepatic bile acid synthesis differentially regulated in 
HIV+ve women presenting with gallstones compared to HIV-ve women? 
 
1.5 Aims, Objectives and ethical approval of this study 
1.5.1 Main Aim 
To determine differences in clinical profiles and regulators of hepatic cholesterol and bile acid 
metabolism in HIV+ve Black South African women on ART presenting with gallstones compared to 
HIV-ve Black South African women with gallstones. 
1.5.2 Objectives 
1. To compare the classical risk profiles (age, BMI, children, family history) and lipogram (LDL-
c, HDL-c, triglycerides, total cholesterol) data between HIV+ve women with gallstone disease 
and HIV-ve women with gallstone disease 
2. To measure the hepatic expression of genes involved in cholesterol homeostasis (LDLR, 
ABCA1, HMGCR) and the transcriptional regulators of these genes (SREBP2, miR-148a) in 
HIV+ve women with gallstones relative to HIV-ve women with gallstones 
3. To measure the hepatic nuclear factors (HNF4a, HNF1a, LXR) that regulate bile acid synthesis 




1.5.3 Ethical approval  
Full ethics approval was granted by the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (BREC), reference number BE276/16 (addendum 1). Permission to conduct the research 
was granted by King Edward VIII (Durban, South Africa) hospital management (addendum 2). 
 
1.6 Overview of this thesis  
This thesis consists of 5 chapters (including the current chapter) 
1.6.1 Chapter 1 
This chapter presents the background, aim, objectives and significance of the study as well as providing 
a general outline of the thesis, its structure, the literature review and methodology. 
1.6.2 Chapter 2  
This chapter presents the results of a case series study, comparing known risk factors of gallstone 
formation in HIV+ve and HIV-ve Black South African women presenting with symptomatic stones for 
cholecystectomy. The study sought to evaluate if the risk factors in HIV+ve women differ to that of 
HIV-ve women. The manuscript is presented in the form of a journal article titled “Symptomatic 
Gallstones and HIV in Black South African Women: Changing trends of gallstone disease?”. This 
manuscript is currently under review at the Southern African Journal of HIV Medicine. Submission ID 
1208. 
1.6.3 Chapter 3 
This chapter presents the results of a case series study, comparing hepatic expression of cholesterol 
homeostasis genes and microRNA (miRNA) regulators of the selected genes in HIV+ve and HIV-ve 
women presenting with symptomatic gallstones. This study sought to evaluate hepatic expression of 
key genes in cholesterol metabolism (LDLr, HMGCR, ABCA1) and transcriptional regulators of these 
genes (microRNA-148a, SREBP2) in HIV+ve women on ART presenting with gallstones. The 
manuscript is presented in the form of a journal article titled “Hepatic expression of cholesterol 
regulating genes favor increased circulating low-density lipoprotein in HIV infected patients with 
gallstone disease: A preliminary study”. This manuscript is currently under review at the BMC 
Infectious diseases Journal. Submission no. 4d005632-284f-4741-a5a7-6ee6dc5cfb4c 
1.6.4 Chapter 4 
This chapter presents the results of a case series study, evaluating the expression of HNF1α, HNF4α, 
LXRb and miRNAs (HNF4α specific: miR-194-5p and miR-122*_1) that regulate CYP7A1 
transcription in HIV+ve Black South African women on combination antiretroviral therapy (cART) and 
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presenting with gallstones relative to HIV-ve women with gallstone disease. The manuscript is 
presented in the form of a journal article titled “Dysregulation of hepatic nuclear regulators of bile acid 
metabolism in HIV-infected women with gallstones”. This manuscript is currently under review at 
Digestive Diseases and Sciences. Submission ID: DDSJ-D-20-03193.  
1.6.5 Chapter 5  
This chapter is a discussion of study findings, strengths and limitations as well as a conclusion which 
contains some observations on the findings of this study, suggests futures plans and makes 




















1.7 Literature Review 
1.7.1 Introduction 
The formation of cholesterol gallstones is complex and usually involves a combination of genetic and 
environmental factors including lifestyle. Most research into the actual cause and risk factors of 
gallstones are performed in Europe and some South American countries with a paucity of data in Africa. 
This oversight maybe in part due to the historically lower incidence amongst black South Africans 
(7,11) compared to the rest of the world, and part due to the focus on the four other  concurrent health 
crisis, specifically HIV, maternal death, malnutrition and other non-communicable diseases (12). 
Traditionally, gallstones were a disease exclusive to Caucasians, however in South Africa, particularly 
amongst black South Africans evidence would suggest that there is a rapid increase in recent years (11). 
Urbanization together with urbanization of diet with an increase in prevalence of obesity amongst Black 
South Africans is currently the only anecdotal explanation for this increase, however other possible 
influential factors such as HIV have not been studied (8). The growing concern around metabolic 
disorders in HIV endemic settings further warrants evaluation of the effect of both the virus and its 
chronic treatment on the formation of gallstones in a population where gallstones was previously 
virtually non-existent.  Further investigation into the epigenetic regulation of hepatic cholesterol 
metabolism in patients with gallstones together with a closer look at HIV and ART influence on 
cholesterol metabolism warrant more attention and research. The effects of HIV infection on cholesterol 
metabolism independent of ART, and the added effects of ART on cholesterol metabolism, poses a risk 
for cholesterol precipitation in bile and thus increases the risk of gallstone formation. Patients on 
protease inhibitors (PI’s) have the greatest risk, but this does not negate the effect of first line therapy 
without PI’s due to the direct effect of HIV and nucleoside reverse transcriptase inhibitors (NRTIs) on 
cholesterol homeostasis. Newer drugs such as Integrase inhibitors are promising and have less effect on 
cholesterol homeostasis. However, the exact mechanism of how HIV and ART directly affect gallstone 
formation is not known. Thus, further studies like these presented in this thesis on the effect of HIV and 
ART on cholesterol and bile acid metabolism might give us a better understanding and help curb this 
high disease burden of GD on our already strained health system. 
1.7.2 Epidemiology of cholesterol gallstones 
The incidence of gallstones (the frequency of developing gallstones over a specific time period, usually 
expressed as per year) is difficult to illicit and thus there are is a lack of available data. The prevalence 
of gallstones (the number of individuals with gallstones at any point in time) is more commonly reported 
and largely based on ultrasound evaluation (13). The worldwide prevalence of gallstones varies amongst 
population groups affecting 10-15% of Caucasian adults in developed countries (6) and more than 85% 
are of the cholesterol type (14). However, reports range from as high as 70% in American Indians (15), 
to as low as 5% in Black Americans and sub-Saharan Africans (6). This low prevalence of gallstones 
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in Sub-Saharan Africa although quoted in more recent literature (5) are from studies dating back to 
1989 (7). A recent review by Khan et al (2020) of cholecystectomies in South Africa would suggest 
that the prevalence may be much higher (8). What is constant however amongst all population groups 
is a female predominance mainly in the younger years (16).  
 
1.7.3 Risk factors for cholesterol gallstones  
1.7.3.1 Age 
Both human and mice studies have demonstrated that gallstone incidence increases with age. In humans 
it is more common in older age categories peaking at age 34 and continuing to rise above 75 (17). Age 
results in greater intestinal absorption of cholesterol, greater biliary excretion of cholesterol and reduced 
hepatic synthesis and biliary excretion of bile salts. Also, there is a relative hypoperfusion of the 
gallbladder wall resulting in gallbladder dysfunction, together with decreased gallbladder wall 
contraction. These findings have been demonstrated in mice by Wang et al. (2002) (18). They showed 
that in mice with lithogenic diets (1% cholesterol, 0,5% cholic acid and 15% butter fat), there is up 
regulation of HMG-CoA reductase activity and a down regulation in 7 alpha-hydoxylase (CYP7A1) 
activity with increasing age (18).  
1.7.3.2 Gender 
Oestrogen is the hormone that is linked with gallstone disease. Women of child bearing ages, pregnant 
women, women that are on hormone replacement therapy or had a previous history of high dose 
unopposed oestrogen (>50mcg) contraception, have 2-3 times higher incidence of gallstones. The high 
oestrogen levels in pregnancy are associated with increased cholesterol secretion in bile, whilst the high 
progesterone levels cause a decrease in bile salts and decreased contractility of the gallbladder wall 
resulting in precipitation of cholesterol (19). Males with cirrhosis of the liver have higher oestrogen 
levels and thus have increased incidence of gallstones (20).  
1.7.3.3 Weight 
Obesity and rapid weight loss are linked to increased gallstones formation. The amount of cholesterol 
synthesized and secreted in bile is directly proportionate to being overweight and thus it is not surprising 
that a direct proportionate relationship to the incidence of symptomatic gallstone per year to the body 
mass index (BMI) exists as well (21). In patients where BMI is adjusted for, weight cycling in these 
patients is also at an increased risk of gallstone formation with larger fluctuation and more weight cycles 
being associated with the highest risks (22). Whilst normalization of weight results in normal 
concentrations of cholesterol in bile, rapid weight loss either non operatively or operatively in the form 
of gastric bypass surgery results in gallstone formation in greater than 50 % of patients. Mechanisms 
8 
 
involved are increased biliary saturation secondary to increased cholesterol mobilization, increased 
nucleation due to changes in bile arachidonate and glycoprotein concentrations, and elevated levels of 
mucin and calcium in bile (23). 
1.7.3.4 Diet and Exercise 
The amount of cholesterol in bile is increased with high levels of cholesterol intake. Refined 
carbohydrates are also found to increase cholesterol saturation in bile. Diets low in fibre, result in low 
intestinal transit time promoting absorption of secondary bile acids (24).  An increase in cholesterol in 
bile due to decreased enteral stimulation and the decrease in bile salts from an interruption in the 
enterohepatic circulation results in the precipitation of cholesterol in bile in patients with prolonged 
fasting / parenteral nutrition (25). Long-term parenteral nutrition promotes gallbladder dilatation and 
hypokinesia (25). 
Protective diets include 2-3 cups of coffee a day, small doses of alcohol and poly- and monounsaturated 
fats and nuts and vegetable protein (26–28). Regular vitamin C supplementation may be protective as 
vitamin C deficiency in guinea pigs leads to cholesterol supersaturation (29). 
Men who perform 30min of endurance type exercise 5 times a week independent of weight loss have a 
reduced risk of symptomatic gallstones while women with recreational activity reduces their risk of 
cholecystectomies (30,31).  Evidence for female patients being protective against gallstone by 
exercising are lacking. 
1.7.3.5 Dyslipidemia  
Cholesterol is in solution in bile due to specific percentage concentrations between itself together with 
bile salts and lecithin. An increase in cholesterol or a decrease in bile salts and lecithin, results in 
cholesterol precipitation and gallstone formation (3). There is a correlation between serum total 
cholesterol, Apolipoprotein B, C2, C3 and the amount of cholesterol saturation in bile. Also, there is a 
correlation with the levels of serum high-density lipoprotein (HDL) with the amount of lecithin and bile 
acids in bile (32). This indicates that serum cholesterol and low-density lipoprotein (LDL) may be an 
attributing factor to gallstone formation while serum HDL might be protective. 
1.7.3.6 Insulin resistance 
A number of studies have linked type 2 diabetes (insulin resistance diabetes), obesity and 
hyperlipidemia to cholesterol gallstone formation, the so-called metabolic syndrome or syndrome X 
(15,33). The basic pathophysiological cause of this syndrome is insulin resistance and results in 
coronary heart disease, stroke, type 2 diabetes and cholesterol gallstones. In control subjects with insulin 
resistance/ hyperinsulinemia, and in non-insulin dependent diabetes patients with insulin treatment, an 
increase in biliary cholesterol secretion has been demonstrated (34). The exact role of hyperinsulinemia 
on gallbladder emptying and mechanisms of bile secretion has not been evaluated. 
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1.7.4 Types of gallstones 
Gallstones are classified into three categories determined by cholesterol concentration viz, a cholesterol 
stone, a pigment stone and a mixed stone. If the cholesterol concentration is higher than 70%, these are 
classified as cholesterol stones. Cholesterol stones are by far the most common accounting for up to 
75% of all gallstones (35). Pigment stones (contain <30% of cholesterol) are due to crystallization of 
calcuim bilirubinate and can occur in 2 forms; either black or brown. Black stones arise as a result of 
increased bilirubin usually from haemolysis whereas brown stones occur as a result of stasis and 
infection, most commonly outside the gallbladder within the bile ducts (36). Biliary cholesterol super 
saturation is thus the main prerequisite for the formation of cholesterol gallstones and therefore stands 
to reason that an in depth look at the mechanism of cholesterol precipitation and the risk factors 
contributing toward this be reviewed. 
 
1.7.5 Mechanism of cholesterol gallstone formation 
1.7.5.1 Supersaturation of cholesterol in bile  
Cholesterol is integral for cellular function. It plays an important role in the production of steroid 
hormones (including testosterone and oestrogen) and vitamin D, and supports all cell membranes in the 
body (37). It is also the starting point for bile salts for the breakdown and absorption of the body’s 
ingested fats. The liver is central to regulation of cholesterol in the body.  Not only does it manufacture 
cholesterol and thus is the source of most of the body’s cholesterol, it also removes cholesterol from 
the body in the bile where it can be excreted in the faeces. 
Bile is 97% water, 0.7% bile salts, 0.2% bilirubin and 0.51% fats (cholesterol, fatty acids, and lecithin). 
Cholesterol is totally insoluble in water and highly soluble in bile (38). This is achieved with micelle 
formation together with bile salts and lecithin. In cholesterol gallstones when cholesterol supersedes its 
saturation point, it results in cholesterol microcrystal formation which inevitably leads to gallstone 
formation (38).  This can either be due to an increase in cholesterol content in bile or a decrease in bile 
salt and lecithin content in bile, or a combination of both.  Admirand et al. (1968) eloquently 
demonstrated this in a triangular relationship between the three components of bile (cholesterol, bile 
salts and lecithin) each as a percentage of the total quantity of all three components with other 
components being a constant (3) (figure 1.1). They plotted a line representing the maximum solubility 
of cholesterol in bile with varying proportions of lecithin and bile salts (red line in figure 1.1). They 
found that bile of normal patients without gallstones had a certain percentage combination of the three 
components which kept them in micelle formation and prevented gallstone formation (plotted under the 
red line in figure 1) while bile from patients with gallstones had percentage combinations resulting in 












Figure 1. 1: Admirand’s triangular percentage relationship of cholesterol, bile salts and lecithin 
in bile. (adapted from Admirand et al 1963) 
A combination of these 3 constituents of bile falling under the red line keeps cholesterol on solution in 
micelles, however combinations outside this line results in cholesterol precipitation and gallstone 
formation. 
1.7.5.2 Impairment in gallbladder function  
Gallbladder contraction removes cholesterol crystals and mucus clumps, and absorbs water preventing 
the formation of stones.  Cholesterol gallstones occur due to an impaired gallbladder wall contraction 
and wall inflammation. Cholesterol supersaturation in bile gets incorporated into the gallbladder smooth 
muscle cell impairing contractility thereby allowing more time for nucleation for cholesterol gallstone 
formation.  Meal-induced release of cholecystokinin (CCK) from the duodenum is the principal factor 
driving gallbladder smooth muscle contraction. CCK-1-receptors-deficient mice result in a significantly 
higher prevalence of cholesterol gallstones (39). Pregnancy, obesity, rapid weight loss, diabetes 
mellitus, and total parenteral nutrition are known to reduce CCK release from duodenum and 
predisposes to cholesterol gallstone formation (40).  
The gallbladder wall is exposed to detergent bile salts, unesterified cholesterol and bacteria, all of which 
could induce inflammation. In mice, Helicobacter subspecies causes wall inflammation playing a 
significant role in the pathophysiology of cholesterol gallstone formation, however their role in human 
gallstone pathogenesis remains to be defined despite various helicobacter species and antibodies to 
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Helicobacter hepaticus being detected at increased frequency in human gallbladders of gallstone 
patients (41).  
1.7.5.3 Impairment of enterohepatic circulation 
The enterohepatic circulation refers to the movement of bile acid (BA) from the liver to the small 
intestine and back to the liver. In the liver BA’s traverse the hepatocyte and are actively secreted into 
canalicular bile, completing the enterohepatic cycle. Ninety-five percent of BA are absorbed in the small 
intestine and the remaining 5% plays an important part in microbiological transformation in the large 
intestine and are lost in the faeces (42). Beyond BA’s role in solubilizing lipids for absorption, it has 
many physiological roles and thus maintaining the equilibrium of the enterohepatic circulation therefore 
making secretion and absorption rates critical. An increase in absorption may contribute to the 
development of nonalcoholic liver steatosis, whereas a malabsorption results in increased hepatic bile 
acid synthesis and increased intestinal luminal concentrations which may lead to bile acid diarrhea (43). 
Patients with impaired intestinal mobility and a prolonged intestinal transit time are at risk for 
gallstones. These patients were found to have an increase in secondary hydrophobic bile salt 
deoxycholate and an increase in total and gram-positive anaerobes and more 7α-dehydroxylating 
activity in the caecum compared to normal subjects (44). Ileal disease, resection or bypass results in  
increased calcium and bilirubin with normal cholesterol levels, thus resulting in pigment rather than 
cholesterol stones (45). However chronic distal intestinal infection with Helicobacter species other than 
H. Pylori has shown to increase cholesterol gallstone formation by nucleating cholesterol supersaturated 
bile (41). Bile salt malabsorption is another factor for cholesterol gallstones. Common examples are 
excess dietary carbohydrates and prolonged TPN which causes ileal atrophy (46,47). 
1.7.6 Molecular and metabolic pathogenesis of biliary cholesterol secretion and gallstone 
formation  
The prevalence of GD varies worldwide according to ethnic population groups which suggests that a 
high prevalence of GD in differing ethnic groups is due to the presence of genetic factors. 
Environmental factors however will still play an important role in gene expression. The liver plays a 
critical role in the whole-body cholesterol homeostasis. The excess cholesterol in bile required for 
gallstone formation as described by Admirand (3) can occur in any 1 of 3 steps in the liver; cholesterol 
input to liver, cholesterol production in the liver, and cholesterol output from liver. Each of these various 
steps might be under genetic control encoding for proteins and enzymes and/or influenced through 
intermediate metabolic pathways linked to a variety of environmental factors responsible for amount of 






Figure 1. 2: Representation of source of Bile cholesterol (BC), Bile Acids (BA), and Lecithin 
excretion in bile (prepared by author) 
Free cholesterol (FC) in liver is from 2 major sources; liver production from acetate via HMG-CoA 
reductase (HMGR), and returning cholesterol to liver from peripheral and intestinal sources viz: 
High density lipoprotein (HDL), Low Density lipoprotein (LDL), Very Low Density lipoprotein 
(VLDL), and chylo remanants. These enter the liver via the LDL receptor (LDLr) and the LDL like 
receptor (LRP). Free cholesterol is cleaved by CYP7A1 in to bile acids. Some of the free cholesterol is 
excreted directed into bile as BC. It is thought HDL is a major contributor to BC. Lecithin is 
produced from Phosopholipids (PL). Biliary lipid secretion is mediated by different ABC 

























Representation of source of Bile cholesterol (BC), Bile Acids (BA), and Lecithin excretion in bile. Free 
cholesterol (FC) in liver is from 2 major sources; liver production from acetate via HMG-Coa reductase 
(HMG-CoA), and returning cholesterol to liver from peripheral and intestinal sources viz : High density 
lipoprotein (HDL), Low Density lipoprotein (LDL), Very Low Density lipoprotein (VLDL), and chylo 
remanants. These enter the liver via the LDL receptor (LDLr) and the LDL like receptor (LRP). Free 
cholesterol is cleaved by CYP7A1 in to bile acids. Some of the free cholesterol is excreted directed into 
bile as BC. It is thought HDL is a major contributor to BC. Lecithin is produced from Phosopholipids (PL) 
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Table 1. 1: Coding of genes/proteins/receptors/miRNA/mRNA involved in cholesterol 
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Tabulated according to their respective level of action viz cholesterol input to liver, cholesterol 
production in liver and cholesterol output from liver in the form of bile acids.  Scavenger Receptor 
Class B Type I (SR-BI).  ATP-Binding Cassette Transporter A1 (ABCA1) Apolipoprotein B (ApoB). 
Apolipoprotein E (ApoE). Low Density lipoprotein receptor (LDL-R). MicroRNA-148a (miRNA 
148a). 3-Hydroxy Methyl-Glutaryl Coenzyme A Reductase (HMGR). Acyl-coenzyme A Cholesterol 
Acyltransferase (ACAT). Sterol Regulatory Element Binding Proteins (SREBP). Peroxisome 
Proliferator-Activated Receptors (PPARs). ATP-Binding Cassette, Subfamily G, Member 5 and 8 




1.7.6.1 Molecular and metabolic influence on cholesterol input to liver 
Lipids (cholesterol, triglycerol and phospholipids) are not soluble in water and therefore have to be 
transported in solution with a protein (apolipoprotein). This combination of lipids and protein for 
transport are called lipoproteins (48). There are 4 main types named according to their degree of lipid 
in relation to protein. Those with more lipids are referred to a high-density lipoprotein (HDL), those 
with fewer lipids are referred to as low density lipoprotein (LDL), and those with very less lipids are 
referred to as very low-density lipoproteins (VLDL). Those with very high lipid levels are called 
chylomicrons (49).  
Bile and other enzymes within the intestine break down ingested fat into cholesterol and lipids. The 
enterocytes produce chylomicrons which transport this cholesterol and lipids via the thoracic duct, 
bypassing the liver, directly into the blood stream where triglycerides are extracted and utilized in 
muscle and stored in fat (50). The remaining cholesterol and lipids in the chylomicrons are then 
transported to the liver where the chylomicrons are endocytosed by the hepatocyte and cholesterol and 
lipids are extracted (51). These are then repackaged as VLDL in the liver and transported to muscle and 
fat. Here the muscle and fat further extract triglycerides from the VLDL converting it to LDL. When 
cells are low on cholesterol, they can now utilize cholesterol from the circulating LDL. When cells have 
excess cholesterol, they can package it into HDL and transport it to the liver where the excess 
cholesterol can be excreted into bile.   
Cholesterol input to the liver occurs from returning cholesterol directly from dietary free cholesterol 
returning from the gut and by receptor mediated internalization of chylomicron remnants, VLDL and 
LDL and selective cholesterol uptake from HDL mediated by the scavenger receptor class b, type 1 
(SR-BI) not depicted in figure 1.2 (52). Cholesterol obtained from HDL is selectively transferred to the 
hepatocyte and is used as a preferential source of cholesterol secreted into bile (53). Cholesterol is 
highly insoluble in water and thus high input may result in lithogenic states by the inability of 
hepatocytes to produce sufficient bile acids to eliminate sterols. 
1.7.6.1.1 Scavenger Receptor Class B Type I (SR-BI) 
SR-BI is a multifunctional receptor that has an affinity for HDLs and mediates uptake of cholesterol-
esters selectively (54). It is known that the unesterified cholesterol secreted in bile is preferentially used 
from HDL via the SR-BI receptor pathway (55). This is evidenced by an overexpression of SR-BI 
receptor resulting in reduced plasma HDL and increased bile cholesterol secretion and an under 
expression of SR-BI having the opposite effect (53,56). This then suggests that SR-BI is a candidate 
gene in the reverse transport of cholesterol from plasma to bile in gallstone formation. However, the 
definitive relevance for gallstone formation has not been addressed directly and remains an area of 
controversy (57).  
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1.7.6.1.2 ATP-Binding Cassette Transporter A1 (ABCA1) 
ABCA1 is an important regulator of reverse cholesterol transport (RCT) (58) which is the process of 
removing excess HDL from cells and transporting them to the liver for excretion in bile (59). 
Overexpression of ABCA1 in mice increases plasma HDL-cholesterol levels and hepatic delivery of 
HDL cholesteryl-esters and biliary cholesterol concentrations and regulators of ABCA1 have shown to 
prevent GD in rodents (60).  
1.7.6.1.3 Apolipoprotein B (ApoB) 
ApoB is the main protein of chylomicrons and LDL. There are two types. ApoB48 which is synthesized 
by the gut and ApoB100 which is synthesized by the liver. ApoB is a ligand for LDL-R. Abnormalities 
in ApoB are associated with changes in LDL-C which contributes to the formation of GD in certain 
population groups (61).  
1.7.6.1.4 Apolipoprotein E (ApoE) 
ApoE is the major protein of VLDL and minor protein of HDL. ApoE acts as a ligand for LDL. It plays 
a critical role in regulating biliary secretion of dietary cholesterol and diet-induced cholesterol gallstone 
formation in mice (62). There are three allelic variants of ApoE. ApoE2 ApoE3 and ApoE4. E2 carriers 
present low concentrations of LDL-C and provide protection against GD (63). E4 carriers present higher 
levels of LDL increase uptake of hepatic and biliary concentration of cholesterol and thus have high 
risk of GD (64).  
1.7.6.1.5 Low Density lipoprotein receptor (LDL-R) 
Cells have LDL-R’s on their surfaces which bind to LDL and extract lipoprotein by endocytosis, and 
of all these cells, more than 80% of circulating plasma LDL is cleared by endocytosis at the hepatocyte 
(52). The LDL together with the receptor are endocytosed into the cell and then the receptor is released 
to be re-expressed at the cell surface before the LDL enters the lysosome to be degraded for use. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that decreases the expression of 
LDL-R on the surface by binding to LDL-R at the surface of the cell, prompting endocytosis into the 
cell together with LDL and LDL-R (65). This prevents the release of LDL-R for re-expression, thus 
causing LDL-R to enter the lysosome where it gets degraded together with LDL and therefore is unable 
to re-present itself at the cell surface. PCSK9 is also regulated by SREBP; it increases expression of 
LDL-R to increase LDL absorption into cell but at the same time increases PCSK9 to decrease the 
expression of LDL-R thus decreasing the absorption into the cell (65). Abnormalities in these regulatory 
elements (decreased SREBP2 and LXR, and increase in PCSK9) results in decreased LDL-R expression 
and decreased LDL catabolism resulting in raised LDL serum levels (66). 
The hepatic LDL-R is crucial for maintaining cholesterol homeostasis. This receptor expression is 
regulated by SREBP and liver X receptors (LXR). Abnormalities in these regulatory elements results 
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in decreased LDL-R expression and decreased LDL catabolism resulting in raised LDL levels (figure 
1.3). There are three forms of SREBPs i.e., SREBP 1a, -1c and -2. SREBP 1c is regulated by insulin. 
SREBP 1a and 2 are regulated by intracellular cholesterol concentrations (67). 
 
Figure 1. 3: LDL levels during normal and decreased LDL-R expression (prepared by author) 
Left (Blue) demonstrating normal LDL levels when there is normal LDL receptor expression. Right 
(Red) demonstrating abnormal high LDL levels due to decreased LDL catabolism as a result of 
decreased LDL receptor expression. LDL receptors are regulated by sterol regulatory element – 
binding proteins (SREBPs) and Liver X Receptors (LXRs) 
 
1.7.6.1.6 MicroRNA-148a (miRNA-148a) 
MicroRNA’s (miRNA) are small non coding RNA molecules (containing about 20-24 nucleotides) 
(68). They are regulatory RNA’s that modulate messenger RNA (mRNA) at a post transcription and 




Figure 1. 4: Post-transcriptional repression of LDL-R by microRNA-148a (miR-148a). 
(prepared by author)  
Upregulation of transcription factors like SREBPs and LXRs prompt transcription of the LDL-R gene 
to mRNA. For LDL-R protein to be synthesized the mRNA needs to undergo translation in the 
ribosome. However, miR-148a is capable of binding to the LDL-R mRNA preventing the mRNA from 
undergoing translation. miRNA-bound mRNA is subsequently marked for degradtione  
With respect to gallstones, miRNAs may regulate the tightly controlled homeostatic mechanisms that 
affect bile acid synthesis and secretion; however, the role of miRNAs is still unclear. In a publication 
by Yang et al (2015) (69), gallbladder mucosa of patients with gallstones were analyzed for miRNA 
expression. Of those that were expressed, miRNA target genes whose functions and regulating 
pathways related to gallstones were identified and compared to miRNA expression in patients without 
gallstones (patients with gallbladder polyps were used for comparison). Of significance was an 
upregulated miR-210 which may play an important role in gallstone formation. Serum also contains 
miRNAs. miR-122 which is specific to liver was shown to correlate strongly with liver enzyme levels 
and necro-inflammatory activity (70). Numerous studies have demonstrated miRNA downregulation 
by HIV-1 infection (71,72), and have been implicated in changes in adipose tissue in HIV+ve patients 
(73). This provides enough basis for further investigating miRNA molecular mechanisms of cholesterol 
homeostasis and gallstone formation. 
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Certain miRNA’s have been identified to regulate cholesterol and lipid metabolism however, the 
contribution to derangement in circulating cholesterol and lipid level and its association to cardio 
vascular disease and gallstones remains unclear (74). In a study by Wagschal et al (2015), they 
recognized single nucleotide polymorphism (SNP)’s in patients with abnormal circulating cholesterol 
and lipids and then observed which miRNA was in close proximity to those SNP’s. These miRNA’s 
were then attributed to the coding for the abnormalities (75). The findings are tabulated in table 1.2. 
Table 1. 2: Relationship of abnormal circulating cholesterol and lipid SNP’s with miRNA and 
their associated lipid abnormality (prepared by author) 
 
MiR-148a is located in a gene-poor intergenic region of human chromosome 7 and is predominantly 
expressed in liver. Notably, the expression of miR-148a is significantly increased in the liver of high-
fat diet (HFD)-fed mice (72). 
Out of 159 miRNAs identified to be highly expressed in human liver and modulated by dietary lipids, 
miR-148a emerged as the strongest with highest liver activity and expression in livers of HFD fed mice 
(76). SNP’s in the promoter region of miR-148a are associated with altered LDL-C and triglyceride 
levels in humans (77). 
LDL-R is shown to be directly regulated by miR-148a. miR-148a has 2 binding sites on LDL-R and 
overexpression of miR-148a markedly reduces LDL-R activity and inhibition of miR-148 significantly 
increased the expression of LDL-R. The inhibition of LDL-R expression by miR-148a is highly specific 
as the expression of other cholesterol related genes such as SREBP2 are not influenced by miR-148a 
overexpression (78).  miR-148a has thus shown to decrease LDL binding and uptake while antagonists 
miR-148a increase LDL binding and uptake. Decreased LDL binding and uptake results in increased 
levels of circulating LDL-C and decreased levels of intracellular LDL-C (78). miR-148a expression 
was also shown to be modulated by SREBP1c which is in turn activated by LXR. SREBP1c is key in 
linking the activation of miR-148a by LXR (figure 1.5). When SREBP1c is silenced this activation of 
miR-148a does not occur (78). miR-148a has an opposite effect on HDL-C and decreases cholesterol 
efflux to ApoA1 by decreasing ABCA1 mRNA (78). 
miRNA near SNP’s Associated abnormality in circulating lipogram 
TC LDL -C HDL -C TAG 
miR-128-1 X X   
miR-148a X X  X 
miR-130-b X  X  





Figure 1. 5: LDL-R downregulation by miRNA 148a (prepared by author) 
 
 
1.7.6.2 Molecular and metabolic influence on cholesterol synthesis 
 Although theoretically the increased production of cholesterol by the liver may result in cholesterol 
gallstone formation, results have not shown a specific pattern of abnormalities. Gallstone patients have 
presented with increased or normal activities of hepatic hydroxy-methyl-glutaryl-Co-A reductase 
(HMG-CoA reductase), the rate limiting steps of cholesterol synthesis (79).   
1.7.6.2.1 3-Hydroxy Methyl-Glutaryl Coenzyme A Reductase (HMGR) 
Cholesterol synthesis within the cell is a complex multistep process, which originates from Acetyl-CoA 
and has one major rate limiting step to final synthesis by HMGR enzyme which regulates the conversion 
of HMG-CoA to mevalonate (80). When cholesterol levels are low, there is increased gene expression 
for increased HMGR activity for increased cell production of cholesterol. This enzyme is regulated by 
sterol response element (SRE) that binds to a transcriptional activator SREBP2 within the nucleus and 
turns on cholesterol synthesis genes (66) .  Insulin-induced gene 1(INSIG1) is a protein in the membrane 
of the endoplasmic reticulum (ER) (81).  INSIG1 plays an important role in the SREBP-mediated 
regulation of cholesterol biosynthesis: by binding to the sterol-sensing domain of SCAP (SREBP 
cleavage activating protein) it makes the SCAP/SREBP complex stay longer in the ER, thus prohibiting 
SCAP from carrying activated SREBP to the golgi complex. This ultimately blocks SREBP from acting 
as a transcription factor for the SRE in the promoter region of the HMG-CoA-reductase gene and results 
in a decreased expression of HMG-CoA-reductase (82). It is activated when the concentration of 
cholesterol in the cell is high and binds to HMGR which results in HMGR degradation and thus reduces 
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the production of cholesterol. In mice, when the genes encoding for transcription of HMGR is 
decreased, it decreases cholesterol synthesis which corelates with the reduction in gallstone formation 
(83).  However, in human studies, even though the saturation of gallbladder bile is higher in gallstone 
patients there seems to be no difference in HMGR activity between patients with and without gallstones 
(79). 
 
1.7.6.2.2 Acyl-coenzyme A Cholesterol Acyltransferase (ACAT)  
ACAT is a cellular cholesterol sensor that esterifies the excess of intracellular cholesterol and stores it 
in cytosolic droplets ready for secretion (84).   There are 2 ACAT genes viz ACAT1 and ACAT2. The 
ACAT1 gene encodes a thiolase mitochondrial enzyme, whilst ACAT2 gene encodes cytosolic 
acetoacetyl-CoA thiolase. ACAT genes are strongly expressed in the liver. In humans, ACAT1 is the 
main cholesterol esterification gene opposed to mice where ACAT2 is predominant (85). In both humans 
and mice ACAT deficiency increases cholesterol availability for biliary secretion increasing the risk for 
GD (86).  
1.7.6.2.3 Sterol Regulatory Element Binding Proteins (SREBP)  
SREBP controls lipid metabolism in cells (87). There are 2 types; SREBP1 present in the liver and 
SREBP2 which is ubiquitously present. SREBP1 is involved in activating genes in fatty acid synthesis 
and SREBP2 is involved in activating genes for cholesterol metabolism (87). SREBP2 is a master 
regulator of cholesterol synthesis in the nucleus of the cell by sensing the amount of cholesterol present 
in the cell and regulating the negative feedback mechanism. SREBP2 exists in the ER together with an 
escort protein called SREBP cleavage activating protein (SCAP). When cholesterol is in abundance in 
the cell the SREBP-SCAP combination binds with Insig and doesn’t signal the nucleus to produce more 
cholesterol (88). When the cholesterol level in the cell is low, the SREBP-SCAP combination 
dissociates from the Insig and travels to the Golgi apparatus where it is cleaved. The SREBP2 then 
travels to the nucleus and binds with sterol response elements (SRE) to signal HMGR to produce more 
cholesterol (89). SREBP2 during times of low cholesterol also switches on LDL-R to increase 
cholesterol uptake (figure 1.6).  
1.7.6.2.4 Peroxisome Proliferator-Activated Receptors (PPARs) 
PPARs are nuclear receptors that activate genes involved in FA metabolism and β-oxidation. Decreased 








Figure 1. 6: Diagram of cell demonstrating cholesterol homeostatic control (prepared by author) 
SREBP2 released from Edoplasmic Reticulum (ER) and transported to Golgi apparatus to mature 
SREBP2 during times of low cholesterol. This switches on HMG-COA reductase increasing 
cholesterol biosynthesis, and LDL-R to increase cholesterol uptake. This now increased intracellular 
cholesterol then activates LXR and ABCA1 and ABCG1 to efflux cholesterol from cell. 
 
1.7.6.3 Molecular and metabolic influence on cholesterol output from liver 
The rate limiting step in converting cholesterol into soluble bile salts for excretion into bile is catalyzed 
by CYP7A1 (91). Defects in the regulation of this enzyme is key to the amount of cholesterol and bile 
acids excreted in bile. The output of biliary lipid secretion is also mediated by different ABC 
transporters: ABCG5/G8 for bile cholesterol, ABCB4 for phospholipids and ABCB11 for bile acids 





















Figure 3: Diagram of cell how g SREBP 2 released fr m Edoplasmic Reticulum (ER) and 
transported to Golgi apparatus to mature SREBP 2 during times of low cholesterol. This switches 
on HMG COA reductase increasing cholesterol biosynthesis, and LDL-R to increase cholesterol 
uptake. This now increased intracellular c olesterol the  activates LXR and ABCA1 and ABCG1 to 
efflux cholesterol from cell [4] 
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the bile exceeds that which can be solubilized by micelles, then the excess is dispersed for transport by 
vesicles (higher cholesterol/phospholipid ratio and lower concentration of bile salts) (3). It is in these 
vesicles with a combination of biliary protein presentation that cholesterol nucleation occurs to form 
cholesterol monohydrate crystals (3). Bile mucin is derived from hepatocytes, gallbladder epithelium 
and bile duct epithelium.  Mucin secretion increases especially in the gallbladder when lithogenic bile 
is present resulting in more viscous bile. 
 
1.7.6.3.1 Cytochrome P450 7A1 (CYP7A1) 
CYP7A1 is an enzyme involved in the rate limiting step of converting cholesterol to bile acid for 
excretion (93) (figure 1.7). When the cholesterol concentration within the hepatocyte is increased either 
by increased delivery to the liver or by increased production, CYP7A1 is activated via liver X receptor 
(LXR) to convert cholesterol into bile acid (94). When the cholesterol levels within the hepatocyte 
drops, SREBP is activated which downregulates CYP7A1 and thus decreases conversion of cholesterol 
to bile acid. Bile acid production downregulates/inhibits CYP7A1 via two pathways; (i) activation of 
Farnesoid X receptor (FXR) which in turn activates small heterodimer (SHP), (ii) by activating liver 
macrophages which activate cytokines such as TNF-alfa (95).  Hepatic nuclear factor 1 (HNF-1) is a 
transcriptional factor for FXR (96). Liver Receptor Homologue (LRH1), is an orphan nuclear receptor 
that serves as a tissue-specific competence factor for bile acid synthesis. HNF in rats works via FXR 
and thus downregulates CYP7A1 as depicted in (figure 1.7), but in humans, HNF works directly on 
CYP7A1 and upregulates its expression (97). Also, in rats LXR directly binds to CYP7A1 and 
upregulates it, but LXR in humans does not bind to CYP7A1 (98). Human CYP7A1 doesn’t seem to be 
influenced as much as rodent CYP7A1 by diet, so in humans CYP7A1 influence on gallstone formation 







Figure 1. 7: CYP7A1 regulation by genes and hepatic nuclear factors (prepared by author) 
CYP7A1 is upregulated and downregulated by various genes and hepatic nuclear factors ultimately 
determining the amount of cholesterol converted to bile acid. Solid lines upregulation. Dotted lines 
represent downregulation.  
 
The majority of evidence dating back to as far as 1975 (99), together with more recent evidence have 
demonstrated that a deficiency in CYP7A1 (100), genetic variations in CYP7A1 (101) and inhibition 
of CYP7A1 with lipid lowering drugs like fibrates (102) result in increased cholesterol concentration 




























Cytochrome P450 7A1 (CYP7A1) is an enzyme involved in the rate limiting step of converting 
cholest rol t  bile acid for excreti  [1]. When the cholesterol concentration within the hepatocyte 
















FXR Liver Macrophages 
ER CYP7A1 
Cytokines - TNF LRH 
HNF-1 
HNF - 4 
24 
 
Genetic variations are evidenced by an anecdotal report of brothers with CYP7A1 mutations in genes 
resulting in gallstone formation (104) and in a case control study in 232 Mexican American men with 
CYP7A1 having increased incidence of gallstones (105). In gallstone susceptible inbred mice, 
overexpression of CYP7A1 was protective against gallstone formation (106). 
However, contrary to this finding in two separate reports of Chilean Hispanic and Mapuche subjects 
(known to have one of the highest incidences of gallstones worldwide), an increase in CYP7A1 (107) 
and an increase in bile acid secretion (108) resulted in increased gallstone formation. However, this has 
yet to be demonstrated in other population groups. 
In the first scenario where CYP7A1 is downregulated, there is a decreased conversion of cholesterol to 
bile acid resulting in increased cholesterol secretion and decreased bile acid secretion in bile resulting 
in gallstones. This is in keeping with Admirands theory (3). In the second scenario where upregulation 
of CYP7A1 results in gallstone formation does not conform to this theory. This may be best explained 
by CYP7A1 being upregulated to increase bile acid secretion. A possible explanation for this is an   
impaired enterohepatic circulation of bile acids from malabsorptive terminal ileal disease. Alternatively, 
differing genetics or environmental factors may influence hepatic nuclear factors changing the 
expression of certain target genes.  
When there is down regulation of CYP7A1 this results in decreased bile acid synthesis and increased 
hepatic cholesterol production. This increased hepatic cholesterol downregulates LDL-R in the liver 
which results in increased serum LDL-C (94). 
In a study of rats and mice hepatocytes with ART PI’s by Zhou et al (2006) (109) the following were 
found. In rat primary hepatocytes, CYP7A1 mRNA levels were significantly decreased by atazanavir 
and ritonavir but increased by amprenavir (109). Similar results were obtained in mouse primary 
hepatocytes. Atazanavir and ritonavir also decreased CYP7A1 protein levels and bile acid biosynthesis, 
while amprenavir had no significant effect (109). In a separate study by Williams et al demonstrated a 
decrease in CYP7A1 in mice hepatocytes treated with Indinavir (110). 
 
1.7.6.3.2 Hepatic Nuclear Factors (HNF)  
Hepatic Nuclear Factors are an important group of regulatory nuclear factors in hepatocyte 
differentiation and hepatic metabolism. HNF-1 regulates bile acid metabolism by three mechanisms: 
(111). One, it is a transcriptional activator of bile acid transporters in ileal enterocytes, hepatocytes and 
renal tubules. Impaired HNF-1 function thus causes reduced bile acid reabsorption from the terminal 
ileum, kidney and decreased removal of bile acid from the portal circulation at the liver all resulting in 
decreased bile acid in liver (interruption of enterohepatic circulation of bile acids). Two, it is a 
transcriptional activator of FXR. Impaired HNF-1 function results in reduced FXR expression resulting 
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in decreased levels of SHP-1 which increases CYP7A1 activity and bile acid synthesis (96,111). Three, 
it is at transcriptional activator of hepatic bile acid binding protein which senses intracellular bile acid 
pool. Impaired HNF-1 function results in defective sensing of bile acid stores in hepatocytes 
In rats HNF-1 binds to FXR receptors and in humans HNF-1 binds directly to CYP7A1 (97). In a study 
of mice, Purushotham et al (2012) demonstrated that HNF-1 alpha is a transcriptional regulator of FXR, 
and when HNF-1 alpha was inhibited it resulted in downregulation of FXR with resultant gallstone 
formation (112). 
HNF-4 together with LRH-1, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-
TFII) and Peroxisome proliferator-activated receptor gamma coactivator 1(PGC-1) are required for 
upregulation of CYP7A1. HNF-4 on its own is  unable to upregulate CYP7A1 (113,114). Bile acids 
cause a feedback downregulation of CYP7A1 not only via HNF-1 and FXR but also HNF-4 which has 
a direct binding site on CYP7A1. Normally HNF-4 binds and upregulates CYP7A1, however there is 
evidence that bile acids can downregulate CYP7A1 transcription by reducing the transactivation 
potential of HNF-4 (115). Bacterial endotoxins, pro-inflammatory cytokines (116), TNF-alpha and 
interleukin -1 by macrophages in the liver (117) are known to decrease the activity of CYP7A1. De 
Fabainai et al (2001) demonstrated that HNF-4 is the target transcriptional factor mediating the effects 
of these pro-inflammatory cytokines on CYP7A1 (115). 
 
1.7.6.3.3 Farnesoid X Receptor (FXR) And Liver X Receptors (LXR)  
FXR is a bile acid (chenodeoxycholic and cholic acid) nuclear receptor that regulates transcription of 
genes that are involved in enterohepatic circulation of bile acids thus maintaining bile acid and 
cholesterol homeostasis (118). In order to bind to target genes, it forms a heterodimer with retinoid X 
receptor (RXR) (118). 
Liver X receptors (LXR) are nuclear receptors that act as cholesterol sensors that regulates transcription 
of genes involved in cholesterol transport and metabolism thus maintaining cholesterol homeostasis. 
There are 2 types, LXR-alpha and LXR-Beta. Both also forms a heterodimer with RXR to function 
(119). 
FXR work together to maintain cholesterol in the enterohepatic circulation. FXR downregulates, and 
LXR upregulates CYP7A1 (120). Mostly down regulation of CYP7A1 has been linked to increased 
gallstone formation, except in Chilean Mapuche Indians were up regulation increases gallstone 
formation (108). FXR controls the expression of ABC transporters, ABCB-11 (canalicular bile salt 
export pump in liver), and ABCB-4 (translocates phosphatidylcholine from inner to outer leaflet of 
canalicular membrane). LXR controls ABCG-5 & 8 (involved in pumping cholesterol into bile). 
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In the study by Moschetta et al (2004), FXR knock out mice, fed a lithogenic diet had an increased 
susceptibility to develop gallstones. Administration of the FXR agonist to gallstone-susceptible mice 
decreased the susceptibility to gallstone formation (118). This is more in keeping with the findings of 
the Chilean population where CYP7A1 up regulation results in gallstone formation because FXR 
inhibition is known to up regulate CYP7A1. They also demonstrated that the bile of the FXR knock out 
mice compared to mice with FXR, was more turbid and had the presence of cholesterol crystals. The 
phospholipid and bile salt concentrations were significantly higher; however, the cholesterol 
concentration was the same as mice with FXR. This therefore resulted in a higher cholesterol saturation 
index in the FXR knock out mice resulting in gallstones. Further to this was increased bile salt 
hydrophobicity in FXR knock out mice which is known to be toxic to gallbladder mucosa resulting in 
increased thickness, damage and inflammation to the gallbladder wall which contributes to gallstone 
formation (121). 
 
1.7.6.3.4 ATP-Binding Cassette, Subfamily G, Member 5 and 8 (ABCG5/8) 
ABCG5/8 are important genes in regulating intestinal and hepatobiliary excretion of cholesterol at the 
level of the enterocyte and canalicular respectively (122). In the liver they are the main regulators of 
cholesterol secretion of cholesterol into bile independent of bile acids (123). Mutations in these genes 
result in sitosterolemia, (characterized by increased plasma sterols, hypercholesterolemia, premature 
atherosclerosis, xanthomatosis and impaired biliary cholesterol secretion), which has been identified in 
Mexican American patients whom are at high risk for developing GD (124). Overexpression of ABCG5 
and 8 in mice results in decreased absorption of dietary cholesterol and increased secretion of biliary 
cholesterol however no precipitation of cholesterol was demonstrated indicating that ABCG5 and 
mutations alone are not enough to cause GD (125).  
 
1.7.6.3.5 Small Heterodimeric Partner (SHP) 
SHP works with nuclear receptors and are also expressed in intestine and liver. SHP is upregulated by 
FXR which in turn reduces SREBP-1c expression which reduces CYP7A1 (126). SHP also represses 





1.7.6.3.6 Liver Receptor Homologue (LRH-1) 
LRH-1 is a nuclear receptor. In addition to being expressed in the intestine and liver it is also expressed 
in the pancreas and ovary. It is involved in bile acid synthesis by targeting several genes including SHP 
and CYP7A1 (127).  
1.7.6.4 Cholesterol gallstone genes (Lith genes) 
The concept that cholesterol cholelithiasis could result from a complex interaction of environmental 
factors and the effects of multiple undetermined genes is well supported by epidemiologic 
investigations, clinical observations, and family and twin studies in humans, as well as gallstone 
prevalence investigations in inbred mouse models. Quantitative trait locus (QTL) analysis is a powerful 
genetic method for identifying primary rate-limiting genetic defects and discriminating them from 
secondary downstream lithogenic effects caused by mutations of the primary genes, and the subsequent 
positional cloning of such genes responsible for QTLs, followed by the use of manufactured mouse 
strains with “knockout” or “knockin” of the genes, could lead to the discovery of lithogenic actions of 
gallstone ( LITH ) genes (128). The successfully identification of many candidate LITH genes has 
results from the combined use of genomic strategies and phenotypic studies in inbred strains of mice. 
The orthologous human LITH genes can be identified from the mouse study because there is 
exceptionally close homology between mouse and human genomes, The discovery of LITH genes and 
more fundamental knowledge concerning the genetic determinants and molecular mechanisms 
underlying the formation of cholesterol gallstones in humans will pave the way for critical diagnostic 
and prelithogenic preventive measures for this exceptionally prevalent digestive disease.By quantitative 
trait loci (QTL) mapping of gallstone susceptible and resistant inbred strains of mice the localization of 
additional unknown gallstone genes has been identified in the genetic era of GD. A number of Lith 
genes have been identified viz Lith1 (chromosome 2), Lith2 (chromosome 19), Lith3 (chromosome 17), 
Lith4 (chromosome X) and Lith5 (chromosome 5).  However, Lith1 and Lith2 are the highest associated 
with GD (129). This provides the genetic basis for orthologous human investigation. 
 
1.7.7 Effect of HIV and ART on cholesterol metabolism 
The prevalence of HIV in South Africa is of the HIV-1 type. The majority of patients in South Africa 
are on a fixed drug combination (FDC) regimen (130).  
FDC regimen consisted of three drugs namely; two Nucleoside reverse transcriptase inhibitors (NRTIs) 
drugs [Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) and one Non-nucleoside reverse 
transcriptase inhibitor (NNRTI) [Efavirenz (EFV)]. (130).  Common second line agents include 
Protease inhibitors (PI) [Lopinivar/ritonavir (Aluvia) or Atazanavir/ritonavir]. A number of drugs are 
available for use in third-line treatment: Integrase strand transfer inhibitors (InSTIs) Dolutegravir 
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(DTG) and Raltegravir (RAL), the newer PI DRV and newer NNRTIs (ETR and RPV). (table 1.3). 
According to  Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 
2020 update (131), (DTG) based therapies are now the preferred first-line ART therapy. 
Table 1. 3: Class of antiretroviral drugs, its mechanism of action and effect on lipid metabolism 













Abacavir (ABC)  
Didanozine (ddl)  
Emtricitabine (FTC)  
Lamivudine (3TC)  
Stavudine (d4T)  
















Efavirenz (EFV)  
Etravirine (ETR)  
Nevirapine (NVP)  
Rilpivirine (RPV)  
↑↑HDL,↑Dyslipidemia 
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InSTI’s Inhibition of 
viral 
integration 
Dolutegravir (DTG)  
Elvitegravir (EVG)  




Early inhibitors - Entry 
inhibition 
Selzentry  Neutral effect 
 
Cholesterol metabolism can be affected directly by the HIV-1 virus independent of ART’s or as a result 
of ART use. The mechanisms are described vide infra. 
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1.7.7.1 Effect of HIV-1 on cholesterol metabolism   
The association of HIV RNA levels with lipid levels independent of ART would suggest that the 
replication of the virus has a direct effect on lipid levels. As HIV RNA levels rise, the levels of HDL 
and LDL fall, and the levels of VLDL, cholesterol (TC), and triglyceride (Tg) levels increase (4).   
Cholesterol efflux is a normal physiological process of removing excess cholesterol from cells.  This is 
mediated by cell membrane transporter, ATP binding cassette 1 (ABCA1), which transports cholesterol 
mainly the lipid poor apolipoprotein A1 (apoA1) out of the cell and converts it into mature HDL for 
transport back to the liver. This reverse cholesterol transport is the first step in maintaining cholesterol 
homeostasis in the body.  Upon entering the peripheral circulation, HIV-1 infects hosts lymphocytes 
and macrophages. In order for survival and replication of the virus within these cells it requires large 
amounts of cholesterol within the cell. In fact, the level of inhibition of cholesterol efflux is directly 
proportional to the level of viral replication within the call.  It achieves this by encoding a small protein 
called Negative Regulatory Factor (Nef) which binds to ABCA1 and downregulates it thus preventing 
the efflux of apoA1 cholesterol to HDL. This results in a decreased level of HDL and macrophages that 
are filled with cholesterol which become referred to as foam cells responsible for large amounts of 
cholesterol release during apoptosis (132)  (Figure 1.8). 
 
Figure 1. 8: HIV effect on ABCA1 and ApoA1 in reverse transport of HDL (prepared by 
author) 
Macrophage infected by HIV-1 encoding for protein Negative Regulatory Factor (Nef) which bind to 
ATP binding cassette 1 (ABCA 1) preventing it from transporting Apolipoprotein A1 (apoA1) out of 
the cell and thus preventing it converting to mature High Density Lipoprotien (HDL) and transport to 
the liver. This results in increase apoA1 and cholesterol within the macrophage 
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SREBP2 is a master regulator of cholesterol synthesis in the nucleus of the cell by sensing the amount 
of cholesterol present in the cell and regulating the negative feedback mechanism (see section 1.7.6.2.3). 
In HIV infection, HIV activates SREBP2 to activate sterol response gene TFII-I to induce the 
cholesterol biosynthetic pathway (133). (figure 1.9) 
 
 
Figure 1. 9: HIV effect on SREBP2 and HMG-CoA in cholesterol production (prepared by 
author) 
Increased cholesterol in the cell causes a negative feedback preventing the cleavage of the Sterol 
regulatory binding protein/ SREBP cleavage activating protein (SREBP/SCAP) from insulin signaling 
protein (Insig), thus preventing SREBP 2 from being cleaved in the Golgi and preventing activating 
HMG-CoA reductase (HMG-CoA) from increasing cholesterol synthesis. However, HIV bypasses this 






1.7.7.2 Effect of ART on cholesterol metabolism  
1.7.7.2.1 Protease inhibitors (PIs) 
Under normal conditions, dyslipidemia is prevented by the binding of cytoplasmic retinoic acid-binding 
protein type 1 (CRABP-1) to intracellular retinoic acid. The retinoic acid is metabolized by cytochrome 
P450 (CYP450) or 3A (CYP3A) enzymes which convert retinoic acid to cis-9-retinoic acid. The cis-9-
retinoic acid then binds to the retinoid X receptor-peroxisome proliferator-activated receptor γ (RXR-
PPARγ). This receptor then stimulates adipocyte differentiation and inhibits apoptosis (134).  
Protease inhibitor drugs bind to and inhibit the catalytic region in HIV-1 protease. The problem is that 
the catalytic region in HIV-1 protease and CRABP-1 are very similar and some of the drug binds to 
CRABP-1 thus inhibiting its function and prevents adipocyte differentiation resulting in apoptosis. The 
resultant adipocyte loss, decreased lipid storage and lipids released into the bloodstream cause 
hyperlipidemia (134) (figure 1.10). 
 
Figure 1. 10: Protease Inhibitor effect on RXR and PPAR γ (prepared by author) 
Protease inhibitors bind to Cytoplasmic retinoic acid-binding protein type 1 (CRABP-1) thus 
preventing it from binding to Retinoic acid, which prevents its conversion to cis-9-Retinoic acid, 
preventing the binding to retinoid X receptor-peroxisome proliferator-activated receptor γ (RXR-
PPARγ) which ultimately results in increased apoptosis and hyperlipidaemia 
 
Another mechanism to prevent dyslipidemia, is the binding of low-density lipoprotein-receptor related 
protein type 1 (LRP1) to lipoprotein lipase (LPL) on the capillary endothelium. This LRP1-LPL 
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complex cleaves fatty acids from triglycerides resulting in free fatty acid accumulation in peripheral 
adipocytes (135).  
The problem herein again is the similarity of the catalytic region in HIV-1 protease to LPR-1, resulting 
in some of the protease inhibitor drugs binding to LPR-1 and inhibiting its function. This results in the 
inability to store fatty acids. These fatty acids are then released into the blood stream and reach the liver 
where they promote synthesis of LDL and VLDL with a resultant increase in cholesterol concentration 
(135).  
PI’s increase the expression and secretion of proinflammatory cytokines, such as tumor necrosis factor-
alpha, interleukin-1β and interleukin-6. These proinflammatory cytokines alter adipocyte function and 
decrease adiponectin. This results in decreased fatty acid break down (136). PI’s also suppress 
proteasome-mediated degradation of SREBP’s in the liver and adipocytes, thus promoting SREBP 
accumulation in the liver resulting in an increase in the biosynthesis of total TC (136). PI-based therapy 
increases the hepatic synthesis of Tg, and to a lesser extent, VLDL cholesterol (137).  
In Japan, recent studies report an increased rate of cholelithiasis (9,8%) in HIV+ve population which 
maybe mostly related to PI treatment (138). Lin et al (2015) demonstrated that the accumulative 
exposure to atazanavir/ritonavir for over 2 years is associated with a 6.29-fold increase in the risk for 
incident cholelithiasis (139). 
1.7.7.2.2 Nucleoside reverse transcriptase inhibitors (NRTIs) 
The most widely known adverse effect of NRTIs is mitochondrial toxicity having implications for ATP 
production and beta-oxidation of fatty acids. DNA polymerase-γ (DNA pol-γ) is a nuclear- encoded 
polymerase that regulates the replication of mitochondrial DNA (mtDNA) in cells (140). As the site of 
cellular energy production through oxidative phosphorylation and via the mitochondrial respiratory 
chain, mitochondrial dysfunction leads to compromised energy production and increased free radical 
production (141). NRTI’s inhibit DNA pol-γ, resulting in decreased mitochondrial DNA, with resultant 
respiratory chain dysfunction and decreased cellular energy. This decreased energy in adipocytes due 
to mitochondrial depletion results in metabolic disorders within the adipocytes with resultant increase 
in plasma lipid levels (142).   
1.7.7.2.3 Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTI’s have not been typically linked to derangements of lipid metabolism however Efavirenz has 
specifically shown to have some effect on lipids. At high concentrations it alters the magnitude of 
adipocyte differentiation and prevents murine pre-adipocytes from accumulating lipids. It increases the 




1.7.7.2.4 Intergrase strand transfer inhibitors (InSTI’s) 
InSTI’s have been touted as not affecting cholesterol metabolism which may have a big impact on 
preventing CVD and GD in these subsets of patients. However, there are growing reports of weight gain 
with the use of InSTI’s (143–145) , especially in Black African women (146). In fact, one study showed 
a greater increase in abdominal fat compared to PI’s (147).  This is concerning considering that a large 
proportion of patients with CVD and GD are linked to obesity, and in particular abdominal fat. 
 
1.7.8 Conclusion 
Cholesterol gallstones are formed due to the supersaturation of bile with cholesterol. The process as to 
how this occurs is complex and involves a combination of environmental and genetic factors 
summarized above. As the liver is the most important route in eliminating the bodies cholesterol via 
bile an in-depth study and understanding into the livers trafficking of cholesterol in terms of its input, 
manufacturing and secretion of cholesterol is explained above and forms the basis for any further 
investigation into the pathogenesis of gallstones. Despite HIV affecting cholesterol metabolism directly 
and from ART’s as outlined above, there is a paucity of data regarding its role in the pathogenesis in 
gallstone formation.  In this thesis study we therefore attempt to explore the possible risk factors and 
pathogenesis of gallstones in this subset of patients by using information obtained in this literature 
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Chapter 1 literature review provided an overview of GD, the current understanding of its pathogenesis 
in HIV-ve humans and murine subjects and a background on HIV and ART and how it may potentially 
be involved in the de-novo pathogenesis of GD. In order to seek differences in HIV+ve and HIV-ve 
patients with gallstones a comparative case series study was conducted. 
 
This chapter responds to objective 1 of this study viz to compare cholesterol levels and known risk 
factors and demographics for cholesterol gallstone formation in HIV+ve and HIV-ve in black South 
African women. The chapter is presented in the form of a manuscript entitled “Symptomatic Gallstones 
and HIV in Black South African Women: Changing trends of gallstone disease”. This manuscript is 
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The incidence of metabolic disorders iHIV endemic settings is a prevailing burden in developing 
countries. Cholesterol homeostasis and fat metabolism are altered by HIV and ART, thereby possibly 
contributing to complications such as gallstone formation.  
Objective 
To evaluate established risk factors for the formation of gallstones in HIV+ve Black South African 
women. 
Methodology 
A case series study was conducted amongst all Black South African women undergoing 
cholecystectomy for gallstone disease over a 1-year period at King Edward VIII Hospital, Durban, 
South Africa. Age, BMI, family history of gallstones, oestrogen exposure and lipograms were compared 
between HIV+ve and HIV-ve women. Categorical variables were tested using either the Fisher’s exact 
test or Pearson’s Chi-square test. Means were compared using independent t-tests. For non-normally 
distributed data, the Mann-Whitney test was used. Statistical tests were two-sided, and p values of less 
than 0.05 were considered as statistically significant. 
Results 
A total of 52 patients were assessed, 34 HIV-ve and 18 HIV+ve. The median age of HIV+ve vs HIV-
ve patients was 35 years and 50 years respectively (p=0.015). The HIV-ve group had a statistically 
significant number of patients in the overweight/obese category (BMI > 25kg/m2) compared to the 
normal weight category (BMI <25kg/m2) (p<0.001). The number of obese patients in the HIV+ve group 
however did not reach statistical significance.   
Conclusion  
Gallstone disease amongst the Black South African HIV+ve women group were significantly younger 
and had fewer patients in the obese category. These findings differ from known risk factors of gallstone 
disease in other population groups and in Black South African HIV-ve women. This could be attributed 
to the metabolic alterations caused by HIV infection itself and long-term ART use. Larger cohort 
studie/s are required to elucidate the role of HIV and ART in cholestatic diseases.  
 
Keywords: HIV, ART, Gallstone disease, Cholesterol gallstones, HIV induced cholesterol gallstones, 




South Africa has a population of 57.7 million and it is estimated that 7.52 million (13,1%) are living 
with Human Immune deficiency virus (HIV), higher than any other country (1). Almost 26% of the 
infected reside in the province of KwaZulu Natal (1). Of those infected, 3.9 million patients (52%) are 
on antiretroviral therapy (ART) (1). Most research into the actual cause and risk factors of gallstones 
are performed in Europe and some South American countries with a paucity of data from Africa. This 
oversight maybe in part due to the historically lower incidence of gallstones amongst Black South 
Africans (2,3) compared to the rest of the world, and to the focus on other concurrent health crisis, 
specifically HIV, maternal death, malnutrition and other non-communicable diseases (4). 
Gallstone disease (GD) can present in a variety of ways, including biliary colic, cholecystitis, gallstone 
pancreatitis, obstructive jaundice and even as a risk to gallbladder cancer. The actual cost of GD to the 
already overburdened health care system in South Africa (SA) is not known. However, if extrapolated 
from developed countries, it is rated as the second highest gastro-intestinal cost burden to the health 
care system (5). GD occurs in up to 20% of the population in developed countries, and is reported as 
low as 5% in Sub Saharan Africa (6). Exclusive prevalence reports from SA are reported as low but are 
outdated (reports from 1987) (3). Reasons for this low prevalence reports at the time, were due to the 
low prevalence in Black South Africans (who constitute 80% of the population); historically GD was 
predominantly observed in Caucasians. Since these earlier reports, there has been an exponential 
increase in the incidence of GD in Black South Africans (2,3). Lifestyle factors, especially urbanization 
of Black South Africans and consumption of foods high in fats and low in fibre have seen a surge in 
high body mass index (BMI) in this population, an established risk to gallstone formation (7). This rise 
in gallstone incidence amongst Black South Africans is paralleled with the rise in incidence of HIV and 
the judicious role out of highly active ART.  
The introduction of ART has changed the spectrum of disease of HIV from that of a terminal illness to 
a chronic, manageable disease. An unprecedented HIV positive (+ve) population with an extended life 
span has seen the emergence of adverse metabolic outcomes that resemble metabolic syndrome defined 
as a cluster of biochemical and physiological abnormalities associated with the development of 
cardiovascular disease and type 2 diabetes characterised by hypertriglyceridemia, low high-density 
lipoprotein (HDL) cholesterol, and insulin resistance, which is known to predict increased risk of 
cardiovascular disease (CVD)(8). There is no one common underlying pathology for this metabolic 
syndrome as each component has different causes, but it is thought that the pathology in HIV+ve 
patients differ from HIV negative (-ve) patients as increased waist circumference occurs less frequently 
(8). Factors contributing to these metabolic outcomes are the host response to HIV infection, specific 
ART drugs, and HIV-associated lipodystrophy (8). The restoration to health also allows metabolic 
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syndrome to manifest in those who were genetically predisposed. This makes HIV+ve patients 
vulnerable to higher incidences of CVD in the absence of known risk factors such as smoking (8).  
 
Like metabolic syndrome, the pathogenesis of GD is well established. However, unlike metabolic 
syndrome specific to HIV, gallstones specific to HIV has not been studied. Gallstone formation occurs 
due to supersaturation of cholesterol in bile, and this supersaturation has been attributed to risks 
commonly referred to the 5 “F”s (Female, Fat, Fertile, Forty and Family history) (9). The observed 
metabolic changes in HIV+ve patients may contribute to GD, as these patients are known to have 
increased circulating lipid levels. The evidence for this is that lipid levels rise concomitantly with HIV 
RNA levels independent of ART. Further, ART use increases lipid release into the bloodstream, thus 
both resulting in hyperlipidaemia (10). This may in turn make HIV+ve patients vulnerable to higher 
incidences of GD without known risk factors such as obesity. 
 
To date, there have been no studies investigating the risk factors of gallstone formation in Black South 
Africans since its first report of their surge in this population group in the early 1990’s (11). Whether 
or not they conform to the same risk factors such as obesity as observed in largely Caucasian populations 
is yet to be determined. We compare well known risk factors for gallstone formation to validate if 
HIV+ve patients are in accord with these risks and compare them to our HIV-ve population in Black 
South African women. This report is thus the first in addressing this issue.  
 
METHODS 
A case series study was conducted, comparing known risk factors of gallstone formation among 
HIV+ve and HIV-ve Black South African women presenting with symptomatic stones for 
cholecystectomy. All patients over the age of 18 years undergoing a cholecystectomy for GD (including 
biliary cholic, cholecystitis, jaundice and gallstone pancreatitis) from King Edward VIII hospital, 
Durban, South Africa during January to December 2017 were included in this study.  
Informed consent was received from all study participants with a standard consent form in 2 of the 
official main languages of SA (English and Zulu), for gathering information including voluntary 
counselling and testing for HIV, if not tested prior to cholecystectomy.  Full ethics approval was granted 
by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC), reference 
number BE276/16. Permission to conduct the research was granted by King Edward VIII (Durban, 
South Africa) hospital management.  
Clinical parameters of patients including, sex, age, race, BMI, family history of gallstones, lifestyle 
parameters (history of contraception/hormone use) and co-morbidities (HIV status, including ART use 
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or not) were assessed by questionnaire. Patients undergoing cholecystectomy for reasons other than 
gallstones where incidental gallstones were found were excluded from the study. Patients whose HIV 
status was unknown or who refused testing after voluntary counselling were also excluded. 
Haematology and serology were used for the quantification of viral loads (VL) and CD4+ lymphocyte 
(CD4+) counts for HIV+ve patients and lipograms (including triglyceride, high density lipoprotein 
(HDL), low density lipoprotein (LDL) and total cholesterol) were performed on all patients. 
Statistical analyses were performed using R Project for Statistical Computing. Descriptive statistics 
such as frequencies and percentages were used to summarize categorical variables. Central tendency 
and dispersion of data was measured using means and standard deviations for normally distributed 
variables and medians and interquartile ranges for skewed variables. Associations between categorical 
variables was tested using either the Fisher’s exact test or Pearson’s Chi-square test. Similarly, with 
regards to the testing of associations between continuous variables: for normally distributed data; means 
were compared using independent t-tests; for non-normally distributed data, the Mann-Whitney test 
was used. Statistical tests were two-sided, and p values of less than 0.05 were considered as statistically 
significant. 
 
RESULTS   
A total of 55 Black South African women underwent cholecystectomies during the study year.  Three 
patients refused HIV testing after voluntary counselling and were excluded (N=52). Median age of all 





















Age    
Median (Q1-Q3) 50 (31-58) 35 (29-42) p = 0.015 
 Distribution (n, %)  
BMIa    
<25 4 (12%) 5 (36%)  
≥25 30 (88%) 9 (64%) p = 0.099 
Comorbidities    
No 22 (65%) 14 (78%)  
Yes 12 (35%) 4 (22%) p = 0.331 
Oestrogen Exposureb    
Negative 2 (6%) 2 (14%)  
Positive 29 (94%) 12 (86%) p = 0.578 
Family Historyc    
None 23 (74%) 13 (93%)  
Positive 8 (26%) 1 (7%) p = 0.236 
Data missing for: afour, bseven, cseven women 
 
Thirty-four patients were HIV-ve and 18 patients were HIV+ve. Of the 18 HIV+ve patients, 14 (78%) 
were on ART for an average of 4.9 years.  
All patients on ART had undetectable VL, with an average CD4+ count of 569 cells/µl. ART naïve 
patients had an average VL of 89,000 copies/ml and an average CD4+ count of 424 cells/µl.  
HIV+ve were younger than HIV_ve women; median ages of 35 years vs. 50 years respectively 




Figure 2. 1: Comparative age in HIV-ve individuals undergoing cholecystectomy compared to 
HIV+ve patients; **p<0.05 
 
 
The median BMI between the HIV-ve and HIV+ve group was 33kg/m2 (IQR 28-39) and 30kg/m2 [IQR 
24-35] respectively with no statistical significance (p=0.231). However, when separating the BMI into  
a normal weight category (BMI <25kg/m2) and an overweight/obese category (BMI >25kg/m2),  the 
HIV-ve group showed statistically significant number of patients in the overweight/obese category 
compared to the normal weight category (p<0.001). However, the HIV+ve group behaved differently 





Figure 2. 2: BMI comparison of HIV+ve and HIV-ve patients in the normal (<25), 
overweight/obese (>25) categories 
 
Seven percent (1/14) of HIV+ve women compared to 26% (8/31) of HIV-ve women had a positive 
family history of gallstones (Table 1).  
Oestrogen exposure in the form of pregnancies and contraception was higher, 94% (29/31) among HIV-
ve women compared to HIV+ve women, 86% (12/14) (table 1). The average use of oestrogen in the 
HIV-ve group was also higher (5years) compared to the HIV+ve group (2 years).  
Hypercholesterolaemia (>5mmol/l) as a co-morbidity was absent in both groups of Black South African 
women. The prevalence of overall comorbidities (Hypertension, diabetes mellitus, previous 









Lipogram results of patients are reflected in Tables 2 and 3.  







Total Cholesterol (mmol/l)a    
Median (Q1-Q3) 4.73 (3.74-5.51) 4.59 (4.18-5.47) p = 0.766 
Triglycerides (mmol/l)b    
Median(Q1-Q3) 1.12 (0.67-1.45) 1.04 (0.84-1.33) p = 0.670 
HDL (mmol/l)c    
Median (Q1-Q3) 1.18 (0.94-1.35) 0.94 (0.91-1.32) p = 0.866 
LDL (mmol/l)d    
Median (Q1-Q3) 2.85 (2.37-3.77) 3.24 (2.93-3.74) p = 0.167 
Data missing for: afour, bfive, cfive, dsix women 
 
The median values of LDL were higher in the HIV+ve group compared to the HIV-ve group; HDL 
levels were lower among HIV+ve women; These results did not reach statistical significance (Table 
2). 
 
Table 2. 3: Percentage of patients with abnormal lipogram values 






Total Cholesterol groupa    
Normal (<5mmol/l) 19 (63%) 12 (67%)  
Abnormal 11 (37%) 6 (33%) p = 0.815 
Triglycerides groupb    
Normal (<1.7mmol/l) 23 (79%) 15 (83%)  
Abnormal 6 (21%) 3 (17%) p = 1.000 
HDL groupc    
Normal (>1.2mmol/l) 14 (50%) 5 (29%)  
Abnormal 14 (50%) 12 (71%) p = 0.175 
LDL groupd    
Normal (<3mmol/l) 16 (57%) 6 (35%)  
Abnormal 12 (43%) 11 (65%) p = 0.155 




The proportion of abnormal HDL and LDL levels was higher among HIV+ve women as compared to 
HIV-ve women; differences in the groups were not statistically significant (Table 3).  
 
DISCUSSION 
The largest analysis of gallstone pathology amongst Black South Africans dates back to 1987, when 
100 cholecystectomies were performed over a 3-year period. The study demonstrated an exponential 
increase in the cholecystectomy rates in Black South Africans from 1967 to 1987. Analysis of stone 
composition and bile composition was similar to that compared to Caucasians (3). In a comparison 
study of acute pancreatitis over two decades in a single institution in South Africa the incidence of 
gallstone pancreatitis increased by 9.7% with a 3.4% increase in Black South Africans (12).  In another 
study undertaken in the early 1990’s in King Edward VIII Hospital (Durban, SA), 82% of the 156 
cholecystectomies during a 2-year period was on Black South Africans, indicating an increasing 
incidence of GD (11).  However, since the turn of the century there is paucity of data regarding the 
incidence, and more importantly the effect of the HIV endemic and ART on patients presenting with 
GD. Well known risk factors of GD are commonly, increasing age, and what is referred to as the five 
‘’F’s’’ (Female, Fat, Fertile, Forty and Family history) with a raised BMI in patients of child bearing 
age exposed to oestrogen, usually peaking around the age of 40 years together with a positive 1st degree 
family history of gallstones, being the biggest known risk factors for GD (3).  
Age 
It is well known that advancing age is a risk for gallstone formation. In mice with lithogenic diets (1% 
cholesterol, 0.5% cholic acid and 15% butter fat), there was an up-regulation of HMG-CoA reductase, 
the rate limiting enzyme for cholesterol synthesis, with increasing age, and down-regulation in 7 alpha-
hydoxylase (CYP7A1), the rate limiting enzyme in bile synthesis activity, with increasing age (13). 
This results in greater intestinal absorption of cholesterol, greater biliary excretion of cholesterol and 
reduced hepatic synthesis and biliary excretion of bile salts (13). With ageing comes a relative 
hypoperfusion of the gallbladder wall resulting in gallbladder dysfunction, together with decreased 
gallbladder wall contraction (13). The largest study of age to date was a multigeneration registry used 
in Sweden, where the ages of 660,732 patients with symptomatic gallstones were studied. The incidence 
of cases per 100,000 people began to peak between the ages of 30-34 years and continued to rise to the 
ages of 75 and over, indicating an increase in incidence of gallstones with increasing age (14). In our 
study, HIV-ve women were more likely to be older than HIV+ve women.  Previous reports of GD in 
younger patients (under 30 years) attribute this paradigm shift to teenage pregnancy, sedentary lifestyle 
and raised BMI.  In a report of 507 patients in Rawalpindi, 48% of patients with GD were under the age 
of 30 years. The study concluded that high BMI and raised socioeconomic status were associated with 
cholelithiasis in the younger ages (15). In a large study in USA there was a comparison of patients 
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presenting with GD in the Bronx area compared to other counties. HIV+ve patients and pregnant 
patients were excluded. The incidence of gallstones in patients under the age of 20 years did not increase 
over the 15-year study period in counties other than the Bronx county. However, the Bronx county 
demonstrated an exponential increase over time. These patients were predominately female and 
although not specifically analysed in this study group, the assumption drawn for this increase was 
related to concurrent increase in rates of teenage pregnancy and obesity in the Bronx compared to other 
counties (16). The reasons for these younger patients presenting with GD was different from our 
HIV+ve group. In these studies, the young patients correlate with known risk factors viz, raised BMI 
and high teenage pregnancy rates. It is reasonable to accept that these patients are presenting with 
gallstones at a younger age. These explanations however do not conform to our HIV+ve group who, 
when compared to the HIV-ve group, do not display a significantly raised BMI (infra vide). 
Furthermore, the exposure to oestrogen in the form of pregnancies and contraception was also lower 
(infra vide).  It is thus reasonable to assume that the younger age of gallstone presentation in the HIV+ve 
population compared to the rest may be purely linked to the metabolic effects of HIV itself or ART or 
a combination of both. 
Weight 
Up to the late 1980’s GD was a condition almost exclusive to Caucasians. Increasing reports suggesting 
an increase in gallstones amongst Black South African women prompted a screening study of 100 Black 
South African women without any gastrointestinal symptoms in Soweto, Johannesburg. The study 
demonstrated an incidence of 10% of gallstones amongst Black South African women (2). The BMIs 
of the 10% were significantly higher compared to those without gallstones, and this was attributed to 
urbanization and diets higher in fats and lower in fibre. This mirrors the findings in our HIV-ve group 
of Black South African women where a statistically significant number of the women (88%) were in 
the overweight/obese category (BMI >25kg/m2). These findings are not surprising as there is a clear 
link to gallstone formation in patients that are overweight. This is explained by the amount of cholesterol 
synthesised and secreted in bile being directly proportionate to being overweight, resulting in a direct 
proportionate relationship to the incidence of symptomatic gallstone per year to the BMI existing as 
well (17).  
Interestingly there was an absence of a significant number of overweight/obese patients (BMI 
>25kg/m2) in the HIV+ve group.  This may be best explained by weight cycling. In patients where BMI 
is adjusted for, weight cycling in these patients is also at in increased risk of gallstone formation with 
larger fluctuation and more weight cycles being associated with the highest risks (18).  
Rapid weight loss in HIV infected patients is well known and this may be a risk factor for gallstone 
formation that is not necessarily seen only in higher BMI patients.  (19). Whilst normalisation of weight 
results in normal concentrations of cholesterol in bile, rapid weight loss, either non-operatively or 
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operatively in the form of gastric bypass surgery, results in gallstone formation in more than 50% of 
patients. Mechanisms involved are increased biliary saturation secondary to increased cholesterol 
mobilization, increased nucleation due to changes in bile arachidonate and glycoprotein concentrations, 
and elevated levels of mucin and calcium in bile (20). Rapid weight gain after ART initiation therapy 
may also contribute to weight cycling in these patients predisposing them to gallstone formation (21).  
Overall BMI may not be an accurate risk stratifying tool in the development of gallstones in HIV+ve 
patients. In a study looking at the fat distribution in HIV infected patients at different BMI’s the visceral 
adiposity was increased in the normal BMI group (18.5 – 24.9 kg/m2) and the overweight BMI group 
(25.0–29.9 kg/m2) relative to control subjects, but not among those in the obese category (≥ 30.0 kg/m2). 
There could be a link with the increase in visceral adiposity rather than an increase in BMI to the 
development of gallstones in HIV+ve patients compared to HIV-ve patients (22). Furthermore, this 
visceral adipose tissue results in accelerated lipolysis and is what contributes to the high prevalence of 
non-alcoholic fatty disease liver reported up to 30-35% of mono infected patients (patients with HIV 
without hepatitis B or C) (23).  
In the longest follow up of body composition following ART, it was found that continued fat gain after 
96 weeks of treatment was associated with the greatest risk of metabolic disorders (24). Southern 
African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update (25), now 
recommend Integrase strand transfer inhibitors (InSTIs) Dolutegravir (DTG) based therapies as the 
preferred first-line ART therapy. InSTI’s have been touted as not affecting cholesterol metabolism 
which may have a big impact on preventing CVD and GD in these subsets of patients. However, there 
are growing reports of weight gain with the use of InSTI’s (26–28), especially in Black African women 
(29). One study showed a greater increase in abdominal fat compared to PI’s (30); this is concerning 




The hypothesises of family history and GD dates back to as early as the mid 1900’s (31). Since then, 
numerous studies observing familial traits together with genetic mapping have been undertaken to prove 
this hypothesis. In a study of 4581 patients in Copenhagen, Denmark, cross sectional ultrasound 
observation demonstrated a 2:1 positive 1st degree family history of gallstones (32).  In an attempt to 
obviate inaccuracies in reporting family histories by the use of case–control studies with limited sample 
sizes, a multigeneration registry was used in Sweden.  It is the largest, unbiased study of family history 
of GD using a multigeneration registry of 15.8 million people studied over 83 years from 1931 to 2015; 
660,732 people were identified with gallstones. Familial cases accounted for 36% of all gallstones, 
50.9% had a parental family history, 35.1% had a sibling history and 14.0% had a parental and sibling 
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history (14). The familial risk of developing gallstones is 2-4 times normal. There is also growing 
evidence of a genetic influence (33). Because of the homology between mice and human chromosomes, 
much of the genetic studies have been undertaken in mice. What has been identified are 25 lithogenic 
or Lith genes in mice gallstone gene mapping.  The sterol export pumps ATP-Binding Cassette 
transporter gene 5 (ABCG5) and the ATP-Binding Cassette transporter Gene 8 (ABCG8) regulate biliary 
cholesterol absorption and excretion and are closely related to lith 9 gene in chromosome 17 in mice 
which are strong candidates for gallstone formation. In humans’ variants of gene ABCG 5/8, namely 
ABCG5-R50C, and ABCG8-D19h, have increased risk of gallstone formation in Indians, Chinese, 
Chileans and Germans, independent of age, sex and BMI (34). Our HIV-ve group of patients with a 1st 
degree family history of GD was 26% compared to the Swedish study of 36%, and our HIV+ve group 
only revealed a 1st degree family history of 7%. This low prevalence of 1st degree family history of 
gallstones in HIV+ve patients is another risk that deviates from known risk factors of gallstone 
formation. This therefore again points that the risk of gallstones in HIV+ve patients may well be related 
to HIV or the use of ART itself, rather than known risks such as genetic influence contributing to 
gallstone formation.   
Oestrogen 
Oestrogen is the hormone that is linked with gallstone disease, with a 2-3 times higher incidence of 
gallstones in women of childbearing ages, pregnant women, women that are on hormone replacement 
therapy or had a previous history of high dose oestrogen (>50mcg) unopposed contraception. The high 
oestrogen levels in pregnancy are associated with increase cholesterol secretion in bile, whilst the high 
progesterone levels cause a decrease in bile salts and decreased contractility of the gallbladder wall 
resulting in precipitation of cholesterol (35). Males with cirrhosis of the liver also have increased 
incidence of gallstones due to the higher oestrogen levels (36). In this observational study the overall 
combined oestrogen exposure rates of those patients presenting with symptomatic gallstones was 94% 
and 86% in the HIV-ve and HIV+ve groups respectively. The pregnancy rates indicated by the number 
of children in the HIV+ve group (61%) was also lower than the HIV-ve group (79%). Although not 
statistically significant, this may well point to oestrogen being less of a player in the pathogenesis of 
gallstone formation in the HIV+ve group compared to our HIV-ve patients.  
 
Dyslipidaemia 
Cholesterol is in solution in bile due to the specific percentage concentrations between itself together 
with bile salts and lecithin. An increase in cholesterol or a decrease in bile salts and lecithin, results in 
cholesterol precipitation and gallstone formation (9). There is a correlation between serum total 
cholesterol, apolipoprotein B, C2, C3 and the amount of cholesterol saturation in bile. Also, there is a 
correlation with the levels of serum HDL with the amount of lecithin and bile acids in bile (37,38). This 
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indicates that serum cholesterol and LDL may be an attributing factor to gallstone formation while 
serum HDL might be protective, both of which were markedly abnormal in our study population. Both 
HIV itself and ART are known to effect cholesterol metabolism. The association of HIV RNA levels 
with lipid levels independent of ART would suggest that the replication of the virus has a direct effect 
on lipid levels. As HIV RNA levels rise, the levels of HDL and LDL fall, and the levels of very low-
density lipoprotein (VLDL), cholesterol (TC), and triglyceride (TG) levels increase (10). The added 
effects of ART are known to further alter cholesterol metabolism by various mechanisms. Patients on 
protease inhibitors (PI’s) have the greatest risk, but others as in our patient population on first line 
therapy without PI’s are still at risk due to the direct effect of HIV on cholesterol homeostasis. 
 
CONCLUSION 
The formation of cholesterol gallstones is complex and usually involves a combination of genetic and 
a host of environmental factors including lifestyle. Most research into the actual cause and risk factors 
of gallstones are performed in the West with a paucity of data from Africa largely due to the lower 
incidence compared in Africa to the rest of the world.  
Whilst Black South Africans are now being exposed to most known risks such as urbanized diets and 
obesity, it not surprising that the patients in our study presenting with GD show clear risks that are 
linked to those in the western world for a disease that is rife amongst Caucasians. However, what is not 
widely appreciated is whether these risks apply to our HIV+ve population. From these observations, 
these patients do not conform entirely to the normal known risk profile. Black South African HIV+ve 
women with symptomatic gallstones were significantly younger.  
Black South African HIV-ve women conform to the known risk factor of obesity with a statically higher 
BMI whilst HIV+ve women do not.   
HIV+ve women also had fewer 1st degree relatives with GD compared to HIV-ve women, and less 
oestrogen exposure. It is not clear whether it is the HIV disease process itself or the role of ART in the 
pathogenesis of GD in people living with HIV. This requires further investigation as GD has a huge 
cost implication on our already overburdened health care system. Larger cohort studies on the impact 
of HIV and ART on liver function, cholesterol metabolism and their influence on cholesterol saturation 
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Chapter 2 discussed the current stance on GD in Black South African women. From this study it appears 
that HIV+ve group do not conform entirely to the normal known risk profile. Black South African 
HIV+ve women with symptomatic gallstones were significantly younger. Black South African HIV-ve 
women conform to the known risk factor of obesity with a statically higher BMI whilst HIV+ve women 
do not.  HIV+ve women also had fewer 1st degree relatives with GD compared to HIV-ve women, and 
less oestrogen exposure. It is not clear whether it is the HIV disease process itself or the role of ART in 
the pathogenesis of GD in people living with HIV. Although serum lipogram levels were not 
significantly different, as a result of these differing environmental risk factors, a closer look into the 
genetic differences in cholesterol trafficking is required at a level of the liver. Guided by the results 
obtained in Chapter 2, a case-series design comparing hepatic expression of cholesterol homeostasis 
related miRNA in HIV+ve and HIV-ve patients presenting with symptomatic gall stones was conducted.  
Chapter 3 presents a study sought to evaluate the hepatic expression of genes involved in cholesterol 
homeostasis (LDLR, ABCA1, HMGCR) in Black South African HIV+ve women presenting with 
gallstones relative to HIV-ve women with gallstone disease. Further, transcriptional regulators of these 
genes (SREBP2, miR-148a) were evaluated. This is in keeping with objective 2. Chapter 3 is presented 
in the form of a manuscript entitled “Hepatic expression of cholesterol regulating genes favour 
increased circulating low-density lipoprotein in HIV infected patients with gallstone disease: A 
preliminary study”. The manuscript is currently under review at the BMC Infectious Disease Journal. 
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HIV endemic populations are displaying higher incidence of metabolic disorders. HIV and the standard 
treatment are both associated with altered lipid and cholesterol metabolism, however gallstone disease 
(a cholesterol related disorder) in Sub-Saharan African populations is rarely investigated.  
Methods 
This study sought to evaluate hepatic expression of key genes in cholesterol metabolism (LDLr, 
HMGCR, ABCA1) and transcriptional regulators of these genes (microRNA-148a, SREBP2) in HIV+ve 
women on antiretroviral therapy presenting with gallstones. Liver biopsies from HIV+ve women(n=5) 
and HIV-ve women (n=5) were analysed for miR-148a and mRNA expression using quantitative PCR. 
Results 
Circulating total cholesterol was elevated in the HIV+ve group with significantly elevated LDL-c 
levels(3.16±0.64mmol/L) relative to HIV-ve group (2.10±0.74mmol/L; p=0.04). A scavenging receptor 
for LDL-c, LDLr was significantly decreased (0.18-fold) in this group, possibly contributing to higher 
LDL-c levels. Transcriptional regulator of LDLr, SREBP2 was also significantly lower (0.13-fold) in 
HIV+ve women. Regulatory microRNA, miR-148a-3p, was reduced in HIV+ve women (0.39-fold) 
with a concomitant increase in target ABCA1 (1.5-fold), which regulates cholesterol efflux.  
Conclusion 
Collectively these results show that HIV+ve women on antiretroviral therapy display altered hepatic 
regulation of cholesterol metabolizing genes, reducing cholesterol scavenging and increasing 
cholesterol efflux. 







Gallstones account for more than 95% of biliary tract diseases in developed countries affecting 20% of 
the population (1). In South Africa, gallstones were considered an affliction predominantly in 
Caucasians, however there has been an exponential increase in gallstone disease in black South Africans 
over the past few decades (2,3). Metabolic disorders in developing countries are a growing concern, 
paralleled with an increase in human immune deficiency virus (HIV) and a consequent judicious roll 
out of anti-retroviral therapy (ART). Whilst a significant amount of work has linked HIV and ART to 
altered fat and cholesterol metabolism contributing to metabolic syndrome-like effects, diabetes and 
cardiovascular disease (4–7), no studies have looked at gallstone disease in this population.  
Gallstones can be categorised into 3 types - cholesterol, pigment or mixed, dependent on cholesterol 
concentration. Cholesterol stones account for ~80% of all gallstones (8) and is a result of cholesterol 
superseding its saturation point in bile, causing cholesterol microcrystal formation, inevitably leading 
to gallstone formation (9).  Demographic, environmental and genetic factors may all contribute to 
altered cholesterol homeostasis (10), presenting complex molecular events that favour gallstone 
formation. Cholesterol homeostasis is maintained by various endogenous responses involving 
cholesterol synthesis, transport and excretion (11,12). 
Cholesterol biosynthesis is regulated by the rate-limiting enzyme of the mevalonate pathway, 3-
hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase (HMGCR) (13). Transcription of HMGCR is 
controlled by transcription factor sterol regulatory element-binding proteins (SREBP1/2) which in turn 
is regulated by liver X receptors (LXRα/β), both of which act as biological cholesterol sensors (14,15). 
The central role of LXR and SREBP transcription factors on lipid and cholesterol metabolism make 
these prime targets in treating metabolic disorders. Cellular regulation of cholesterol flux also plays a 
key role in maintaining circulating cholesterol levels - Low-density lipoproteins (LDL) are scavenged 
by LDL receptors (LDLr) while a major determinant of high-density lipoproteins (HDL) is efflux pumps 
belonging to the ATP-binding cassette (ABC) family including ABCA1. The genes coding for these 
proteins are considered lithogenic and are implicated in gallstone progression which can be altered 
during HIV infection (16).  Transcriptional regulation of gene expression offers an opportunity to 
identify molecular events influencing disease phenotype.  
MicroRNAs (miRNAs), short non-coding RNA (18-24 nucleotides) are epigenetic modulators of gene 
expression. MicroRNA prevent translation of target messenger RNA (mRNA) by binding via base 
complementarity. Various miRNAs have been associated with metabolic disorders through their 
regulatory function on cholesterol and lipid metabolism genes (17).    The role of miRNA in gallstone 
disease is unclear, however some miRNAs have been identified as regulators of genes involved in 
gallstone formation. MicroRNA-122a and miR-144a directly inhibit cholesterol 7 alpha hydroxylase 
(CYP7A1) influencing the bile acid pool (12). Yang et al. (2015) performed an integrated analysis of 
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miRNA/mRNA networks in gallstones, identifying 17 differentially regulated miRNAs (18). This study 
showed miRNAs that regulated lipoprotein signalling and ABC transporters were significantly altered 
in gallstone patients. MicroRNA-148a is a miRNA that is highly expressed in liver and associated with 
altered LDL-c and triglyceride levels in humans (19). LDLr is shown to be directly regulated by miR-
148a and is linked to gallstone formation in high fat diet fed mice (20). 
Dysregulated miRNA in HIV infection is more well established than miRNA associated with biliary 
tract disorders, with several papers linking altered miRNAs to disease progression, metabolic outcomes, 
treatment responsiveness and biomarkers (21,22). Despite the established link of HIV and ART to 
metabolic disorders, there is a dearth of knowledge on gallstone disease in this population. In Japan, 
studies report an increased rate of cholelithiasis (9,8%) in HIV+ve patients on protease inhibitor (PI)-
inclusive ART (23). Lin et al (2015) demonstrated that the accumulative exposure to 
atazanavir/ritonavir for over 2 years is associated with a 6.29-fold increase in the risk for incident 
cholelithiasis (24). Despite newer integrase inhibitor (II) ART drugs showing lower lipid abnormalities 
than previously used PI-based ART, abnormalities in lipid concentration still occur, and this may be 
reflective either of the viral effects itself, chronic ART use or the persistent inflammation and immune 
activation in these HIV infected patients (25). The present study sought to evaluate the hepatic 
expression of genes involved in cholesterol homeostasis (LDLR, ABCA1, HMGCR) in Black South 
African HIV+ve women presenting with gallstones relative to HIV-ve women with gallstone disease. 
Further, transcriptional regulators of these genes (SREBP2, miR-148a) were evaluated. 
METHODS 
This study utilized a case-series design comparing hepatic expression of cholesterol homeostasis related 
miRNA in HIV+ve and HIV-ve  women presenting with symptomatic gall stones. Ethical approval was 
obtained from the University of KwaZulu Natal. Biomedical Research Ethics Committee (BREC – 
BE276/16). Patients undergoing cholecystectomy for gall stone disease (biliary cholic, cholecystitis, 
jaundice and gall stone pancreatitis) at King Edward VIII Hospital, Durban, KwaZulu Natal, South 
Africa from January – December 2017 were recruited to evaluate known risk factors of gall stone 
formation in HIV+ve and HIV-ve patients. In total 52 patients gave informed consent (standard consent 
form in two official main languages English and isiZulu) for retrieval of a liver biopsy and recording 
of clinical parameters of patients including age, race, BMI, family history of gall stones and 
comorbidities (HIV, hypertension, diabetes, hypercholesterolemia).  
Following the analysis of clinical parameters, five HIV negative (control) and five HIV positive (cases) 
were selected for miRNA and downstream target analysis. Inclusion criteria included women of Black 
African ethnicity between the ages of 18-50, presented with symptomatic cholelithiasis, were all on 
contraceptive for more than one month, and did not have a family history of gallstones. Patients with 
co-morbidities (diabetes mellitus, arterial hypertension, hypercholesterolemia, chronic inflammatory 
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disorders), receiving chronic therapy for the above-mentioned co-morbidities and HIV positive patients 
on preventative TB therapy were excluded. All HIV positive patients were on fixed dose combination 
therapy with CD4 counts above 500 cells/mm3 and undetectable viral loads.” 
The selection of 5 samples for molecular analysis was based on the limited accessibility of molecular 
testing following the inclusion process .  
RNA extraction 
Briefly, liver tissue (1cmx1cm) was submerged in RNAlater® Stabilization Reagent (Qiagen, Hilden, 
Germany) in 2ml cryovials at collection and stored at -80ºC until RNA extraction. The stabilization 
buffer was decanted, and tissue samples were rinsed in 0.1M phosphate saline buffer (PBS) prior to 
RNA extraction via the Qiazol extraction method as per the manufacturer’s instructions. Crude RNA 
was quantified using the Nanodrop 2000 spectrophotometer (Thermofisher Scientific, Waltham, MA, 
Waltham, Massachusetts, USA) and 1µg of RNA was used for complementary DNA (cDNA) synthesis. 
The miScript RT II Kit (Qiagen) was used for miRNA quantification and the QuantiTect Reverse 
Transcription kit (Qiagen) was used for mRNA quantification as per the manufacturer’s instructions.  
MicroRNA-148a and mRNA quantification 
Hepatic expression of microRNA-148a in patients was measured using a miScript Primer Assay specific 
for human miR-148a-3p (Qiagen) as per the manufacturer’s instructions. Briefly, a reaction volume of 
25µl consisting of template cDNA, 2X QuantiTect SYBR Green PCR Master Mix, 10X miScript 
Universal Primer, 10X miScript Primer Assay and nuclease free water was prepared in a MicroAMP™ 
96-Well Base plate (Applied Biosystems, Foster City, CA, USA) and sealed. Thermocycler conditions 
for quantitative PCR were as follows - Initial denaturation (95ºC, 15 min) followed by 40 cycles of 
denaturation (94ºC, 15 s), annealing (55ºC, 30 s) and extension (70ºC. 30 s, fluorescence reading). 
House-keeping gene RNU6 was concurrently quantified for normalization of gene expression. 
Thermocycler conditions and data capturing were performed using the Applied Biosystems Viia7 Real-
Time PCR System.  
Messenger RNA quantification was performed using the PowerUp™ SYBR™ Green Master Mix 
(ThermoFisher) system as per the manufacturer’s instructions. A reaction volume of 10µl was made up 
consisting of 5µl PowerUp® SYBR® Green Master Mix, 1µM of sense and antisense primers and 
nuclease free water. Thermocycler conditions were as follows: 50ºC 2 min, initial denaturation (95ºC, 
15 s), and 40 cycles of denaturation (95ºC, 15 s), annealing (Table 2, 15 s), and extension (72ºC, min). 
Housekeeping genes GAPDH and 18S were concurrently quantified for normalization of results. 
Thermocycler conditions and data capturing were performed using the Applied Biosystems Viia7 Real-




Table 3. 1: Primer sequences and annealing temperatures for quantitative PCR 

























Comparisons of clinical parameters between HIV-ve and HIV+ve  women presenting with gall stones 
were made by performing a Mann-Whitney U Test using Prism 7 statistical software (GraphPad Prism 
Inc, La Jolla, CA, USA). P values <0.05 were considered statistically significant. 
Quantitative PCR analysis of miRNA and mRNA levels was performed using QuantStudio 7 Pro Real-
Time PCR Systems Software (Thermofisher). MicroRNA and mRNA levels were reported as fold 
change expressed as 2-ΔΔCt (RQ min; RQ max). Fold changes >2 and <0.5 were considered significant. 
 
RESULTS 
Analysis of clinical parameters are summarized in Table 1. The HIV+ve group was significantly older 
than the HIV-ve group. The results show that the HIV+ve group had a lower BMI with overall higher 
levels of total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-c) and significantly 








Table 3. 2: Clinical parameters of patients presenting with gall stones (HIV-ve vs HIV+ve) 
 CONTROL 
N = 5 
HIV 









3.640±1.107 4.882±0.9883 0.0986 (ns) 
TRIGLYCERIDES 
(mmol/L) 
0.7640±0.3886 0.8980±0.4909 0.6457 (ns) 
HDL (mmol/L) 1.192±0.2821 1.328±0.5758 0.6526 (ns) 
LDL (mmol/L) 2.096±0.7410 3.160±0.6403 0.0419 
*ns: no significance 
microRNA-148-3p and target gene quantification 
Gene targets of miR-148-3p were confirmed using TargetScan prediction software confirming 
complementary base pairing with ABCA1 and LDLr (Figure 1A). Quantitative PCR results for miR-
148a-3p showed significantly lower hepatic expression in HIV+ve individuals [0.396-fold (RQ 
min:0.297; RQ max: 0.527); Figure 1B]. Analysis of target gene ABCA1 showed higher mRNA levels 
[1.541-fold (RQ min: 1.266; RQ max: 1.875); Figure 1C] while LDLr mRNA levels were significantly 





Figure 3. 1: MicroRNA-148-3p is a regulator of cholesterol metabolism through its binding 
capacity on ABCA1 and LDLr (A). Hepatic expression is significantly lower in HIV positive 
patients (B) with an inverse observation made with ABCA1 mRNA levels (C). LDLr mRNA 
levels were significantly lower in HIV infection (D). 
 
Transcriptional regulation of LDLR via SREBP2 
Following analysis of miR-148a-3p and target genes ABCA1 and LDLr, alternate transcriptional 
regulation of LDLr was investigated to justify the significantly lower mRNA levels observed in HIV 
infected individuals. Quantitative PCR results showed significantly lower SREBP2 (transcriptional 
regulator of LDLr) mRNA levels in HIV positive patients presenting with gall stones compared to HIV-




Figure 3. 2: Quantitative PCR analysis of SREBP2 mRNA showed significantly lower 
expression in HIV positive patients relative to HIV negative controls 
 
Cholesterol metabolism 
HIV+ve women showed higher levels of total cholesterol, therefore the gene responsible for cholesterol 
metabolism was quantified. HMGCR mRNA levels were lower in the HIV+ve group, albeit 
insignificantly [0.595-fold RQ min: 112; RQ max: 1.172); Figure 3]. 
 
Figure 3. 3: Quantitative PCR analysis showed 0.6-fold change in HMGCR mRNA levels in 








Urbanised diets and the consequent rise in obesity amongst Black South Africans has led to gallstones 
becoming more prevalent amongst this population group in recent years. Established risk factors for 
gallstones – over forty years of age, female, pregnancy, overweight, high-fat diet, and being sedentary, 
are all lifestyle or demographic dependent (10). Little is known on the implications of chronic infectious 
diseases like HIV on gallstone disease risk. Our unpublished data evaluating risk factors in HIV+ve 
women (n=18) showed that these patients do not conform to these risk factors, with this population 
being significantly younger to uninfected patients (26). The present study sought to investigate 
molecular events that may contribute to this phenotype by measuring the hepatic expression of 
cholesterol metabolism genes that influence gallstone formation. Biological response to a high fat diet, 
the rate of cholesterol absorption, hepatic cholesterol metabolism and the concentration of cholesterol 
excreted in bile differs between patients with and without gallstones (27). Raised LDL-c in circulation 
is strongly implicated in lithogenic states. Lowered HDL-c levels are also implicated in gallstone 
formation but data regarding this finding has been conflicting in reports (28).  
Mounting evidence suggests the resultant abnormalities are linked to dietary and genetic factors. LDL-
c is cholesterol that is available for delivery and cellular uptake; the circulating concentration is linked 
directly to dietary cholesterol consumption and associated with both cardiovascular disease and 
cholesterol gallstone formation (11,29). HDL-c, excess cholesterol transported from cells to the liver 
for excretion in a process called reverse cholesterol transport, is considered the “healthier” cholesterol 
due to protective properties against atherosclerosis. Lower HDL-c is linked to poorer cardiovascular 
outcomes and is also implicated in cholesterol gallstone formation (30). Elevated activity of cholesteryl 
ester transfer protein (CETP) in patients with gallstones may lower HDL-c and increase LDL-c by 
transferring the lipoprotein from HDL to LDL (31). 
A high circulating LDL-c will result in higher concentrations of cholesterol being delivered to the liver 
for excretion resulting in supersaturation of bile, inevitably leading to gallstone formation.  This is best 
explained by Admirand’s triangular relationship between cholesterol, bile salts and lecithin, where 
biliary cholesterol hypersecretion supersedes the concentration of bile salts and lecithin with resultant 
precipitation and formation of cholesterol stones (9). The cholesterol hypersecretion is due to excess 
free cholesterol pooling in the liver either due to increased HMGCR activity or larger volumes of 
cholesterol returning to the liver. Cholesterol is returned to the liver via one of 4 pathways; via the 
LDLr, via apoE-rich lipoproteins through the LDL receptor-like protein (LRP), via HDL2 free 
cholesterol "exchange," or via nonreceptor-mediated LDL uptake (32).  
Altered cholesterol metabolism, favouring LDL-c is complicit in gallstone formation, among other 
metabolic disorders such as cardiovascular disease. Although HIV and ART are linked to metabolic 
disorders leaning toward this phenotype, little is known of the effects of HIV on gallstone formation. 
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In HIV+ve patients, low levels of HDL-c are congruent with high viral loads, linking this metabolic 
profile directly to the virus itself independent of ART (33). The use of ART reverses these effects.  
LDL-c levels however appear similar to HIV-ve women, but rises dependant on the use of PI-ART (34). 
In HIV+ve men however, there is an inverse relation with LDL-c and HIV RNA levels independent of 
ART, and this may well be a major contributing factor to men being relatively protected against 
gallstones as indicative of the low incidence of gallstones in HIV+ve men (35).  
These findings are not dissimilar to that in our study group where all patients were women and all on 
ART. The use of ART may explain the significantly higher LDL-c, and the slight increase in HDL-C 
in the HIV+ve group compared to the HIV-ve group (Table 1). Altered circulating LDL-c would prompt 
cellular homeostatic responses. As HIV+ve women in our study displayed higher LDL-c, we evaluated 
the first line of hepatic LDL-c uptake. Located on the cell membrane, LDLr is responsible for hepatic 
absorption of LDL, with higher expression reducing circulating LDL-c levels.  The expression of LDLr 
is regulated by various regulatory mechanisms including transcription factors (SREBP2 and LXR) and 
epigenetic regulators like miR-148a. SREBP transcription factors regulate the biosynthetic pathway of 
cholesterol and LDLr by stimulating transcriptional genes containing sterol response elements (36). 
There are 3 isoforms; SREBP1a, SREBP1c and SREBP2. SREBP2 is highly expressed in liver amongst 
other cells. Abnormalities in these regulatory elements (decreased SREBP2 and LXR) results in 
decreased LDLr expression and decreased LDL catabolism resulting in raised LDL-c serum levels (37). 
HIV-1 infection of CD4+ T cells stimulates cholesterol biosynthesis via SREBP2 sterol response gene 
(protein TFII-I) activation for enhanced HIV-1 transcription and HIV-1 replication (38). HIV-1 
transcription is thus modulated by LDL-c, since uptake of LDL-c results in feedback inhibition of 
SREBP2- dependent proteins such as TFII-I (38). The hepatic impact of this in HIV+ve patients with 
gallstones in not known. However, LDLr levels in mononuclear cells of both the blood and liver have 
been found to be down-regulated in HIV+ve patients with lipodystrophy compared to HIV-ve controls 
and HIV+ve patients without lipodystrophy, independent of PI-ART (39).  The pathogenesis of this 
lipodystrophy by down-regulation of LDLr may not be dissimilar to that of gallstone pathogenesis in 
HIV+ve patients as these mimics our findings in this study.   
Cholesterol reverse transport is also an important determinant in cholesterol homeostasis. In this regard, 
the ABC family of efflux pumps plays a significant role in cellular efflux of cholesterol. ABCA1 is a 
major regulator of cellular reverse cholesterol transport by transporting cholesterol, mainly the lipid 
poor apoA1, out of the cell and converts it into mature HDL for transport back to the liver. 
Overexpression of ABCA1 in transgenic mice results in a lithogenic state by increasing plasma HDL-c 
levels, hepatic delivery of HDL cholesteryl-esters and biliary cholesterol concentrations (40). Its 
lithogenic role is further accentuated in gallbladder epithelial cells, where ABCA1 is regulated by LXR 
and RXR and modulates biliary cholesterol concentrations and its excretion (41).  
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ABCA1 expression can be epigenetically regulated by miR-148a. Inhibition of miR-148a increases 
ABCA1 mRNA levels resulting in increased cholesterol efflux to ApoA1, thus increasing plasma HDL-
c (20).  
The effect of HIV on hepatic ABCA1 expression has not been studied, however in order for survival 
and replication of the virus within lymphocytes, it requires large amounts of cholesterol within the cell. 
It achieves this by directly inhibiting ABCA1. The level of inhibition of cholesterol efflux is directly 
proportional to the level of viral replication within the cell.  It achieves this by encoding a small protein 
called Negative Regulatory Factor (Nef) which binds to ABCA1 and downregulates it thus preventing 
the efflux of apoA1 cholesterol to HDL (5). 
Besides its regulatory role of ABCA1, miR-148a is considered a central miRNA in cholesterol and fat 
metabolism. MicroRNA-148a is located in a gene-poor intergenic region of human chromosome 7 and 
is predominantly expressed in liver (20). Notably, the expression of miR-148a is significantly increased 
in the liver of high-fat diet (HFD)-fed mice (20). Out of 159 miRNAs identified to be highly expressed 
in human liver and modulated by dietary lipids, miR-148a emerged as the strongest with highest liver 
activity and expression in livers of HFD fed mice (42).  Lastly, we assessed cholesterol biosynthesis in 
HIV+ve women via HMGCR levels. HMGCR, the rate limiting enzyme in the mevalonate pathway is 
regulated by SREPB2 which up-regulates cholesterol synthesis genes when cholesterol levels are low 
(43). Our study showed the HIV+ve group having lower HMGCR mRNA levels (Figure 3) which may 
be due to cholesterol levels being higher in this group. 
The most obvious limitation of the study is the small sample number. Ideally the study would include 
samples from patients without gallstone disease and patients not on ART. These demographics proved 
difficult to collect in sufficient numbers during the patient recruitment period. Another limitation was 
the large average age gap between the HIV negative and HIV positive groups, which is likely to affect 
the observed results. The study could be enhanced by correlating the expression of these genes in the 
liver with circulating levels of the genes and lipogram data – these statistics would be more powerful 
with a bigger sample size. Furthermore, discrepancies in the duration of ART in the patients may lead 
to variability 
CONCLUSION 
Cholesterol homeostasis is complex, and dysregulation of the regulatory processes involved can lead to 
cholesterol gallstone formation. The impact of a chronic infectious disease, like HIV, needs to be 
considered in the context of rising incidence of metabolic disorders in developing countries. Our 
findings show a significant increase in circulating LDL-c in the HIV+ve group coupled with reduced 
mRNA expression of hepatic LDLr. However, the suppression of miR-148, an epigenetic regulator of 
LDLr, was downregulated in the HIV+ve group. This would indicate a possible alternate pathway in 
the downregulation of LDLr in HIV+ve patients linked with raised LDL-c and gallstone formation and 
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will require further investigation. MiR-148a however did appear to regulate ABCA1 with an inverse 
relationship being observed in the HIV+ve patients. 
 
LIST OF ABBREVIATIONS 
ABC  Adenosine triphosphate binding cassette 
ABCA1 Adenosine triphosphate binding cassette A1 
ART  Antiretroviral therapy 
BMI  Body mass index 
cDNA  Complementary DNA 
CETP  Cholesterol ester transfer protein 
CYP7A1 Cholesterol-7 alpha-hydroxylase 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HDL  High density lipoprotein 
HDL-c  High density lipoprotein cholesterol 
HMG CoA 3-hydroxy-3-methyl-glutaryl-CoA 
HMGCR 3-hydroxy-3-methyl-glutaryl-CoA Reductase   
HIV  Human Immunodeficiency Virus 
LDL  Low density lipoprotein 
LDL-c  Low density lipoprotein cholesterol 
LDLr  Low density lipoprotein receptor 
LRP  Low density lipoprotein receptor like protein 
LXR  Liver X Receptor 
miRNA  microRNA 
mRNA  Messenger RNA 
PBS  Phosphate saline buffer 
PI  Protease inhibitor 
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SREBP Sterol regulatory element binding protein 
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Chapter 3 demonstrated that HIV+ve Black South African women with GD have a higher circulating 
LDL-c with a reduced mRNA LDLr hepatic expression compared to their HIV-ve counterparts with 
GD. However, MiR-148 a known epigenetic regulator of LDLr was also downregulated indicating a 
possible alternate pathway in the downregulation of LDLr in HIV+ve patients. Using this obtained 
information of decreased LDL input of cholesterol to hepatocytes in Chapter 3, focus was shifted into 
looking into the cholesterol output of the hepatocyte.    
Chapter 4 presents a study sought to evaluate the expression of HNF1α, HNF4α, LXRb and miRNAs 
(HNF4α specific: miR-194-5p and miR-122*_1) that regulate CYP7A1 transcription in HIV-infected 
Black South African women on antiretroviral therapy (ART) and presenting with gallstones relative to 
HIV negative women with gallstone disease. This is in keeping with objective 3. Chapter 4 is presented 
in the form of a manuscript entitled “Dysregulation of hepatic nuclear regulators of bile acid metabolism 
in HIV-infected women with gallstones”. The manuscript is currently under review at the Journal of 
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Gallstone formation occurs when the equilibrium between cholesterol and bile acid is altered. HIV 
infected patients on antiretroviral therapy (ART) are prone to hypercholesterolemia, which contributes 
to metabolic disorders. Although cholesterol homeostasis has been studied extensively in HIV, little is 
known regarding the bile acid synthesis pathway which is initiated by cholesterol 7-alpha hydroxylase 
(CYP7A1) and regulated by hepatocyte nuclear factors (HNF1α, HNF4α and LXRb). 
Aim/ Objective 
To evaluate the expression of HNF1α, HNF4α, LXRb and miRNAs (HNF4α specific: miR-194-5p and 
miR-122*_1) that regulate CYP7A1 transcription in HIV+ve Black South African women on ART and 
presenting with gallstones relative to HIV negative patients with gallstone disease.  
Methods 
Black African Women (n = 52) presenting with gallstone disease were stratified based on HIV status. 
The gene expression of CYP7A1, HNF1α, HNF4α, LXRb, miR-194-5p and miR-122*_1 was determined 
using RT-qPCR. Messenger RNA and miRNA levels were reported as fold change expressed as 2-ΔΔCt 
(RQ min; RQ max). Fold changes >2 and <0.5 were considered significant.  
Results 
HIV+ve women were older in age (p = 0.0267) and displayed higher low-density lipoprotein cholesterol 
(LDL-c) (p = 0.0419), CYP7A1 [2.078-fold (RQ min: 1.278; RQ max: 3.381)], LXRb [2.595-fold (RQ 
min: 2.001; RQ max: 3.000)] and HNF1α [3.428 (RQ min: 1.806; RQ max: 6.507] levels. HNF4α 
[0.642-fold (RQ min: 0.266; RQ max: 1.55)], miR-194-5p [0.527-fold (RQ min: 0.37; RQ max: 0.752)] 
and miR-122*_1 [0.595-fold (RQ min: 0.332; RQ max: 1.066)] levels were lower in HIV+ve women.  
Conclusion 
HIV+ve women with gallstone disease displayed higher LDL-c levels and increased markers for bile 
acid synthesis, which was evident by the elevated expression of CYP7A1, HNF1α and LXRb. This could 








The advent of antiretroviral therapy (ART) in human immunodeficiency virus (HIV) treatment was one 
of the most significant advances in modern medicine. The HIV epidemic went from a public health 
crisis to a chronic treatable disease as ART markedly extended the life expectancy of infected 
individuals. While the large-scale rollout of ART has made a positive impact on the outcomes of HIV 
morbidity and mortality, there now emerges an unprecedented population of people aging with HIV (1–
3). This has led to a new phenomenon - an “epidemic within an epidemic”, with disorders of metabolism 
becoming increasingly prevalent in HIV+ve individuals on ART. These range from acute to chronic 
adverse effects with the most common being cardiovascular disease, lipodystrophy, diabetes and 
metabolic syndrome (4–8). Altered glucose metabolism and hypercholesterolemia are hallmarks of HIV 
patients on chronic ART (6,8,9). Kato et al. (2020) reported higher low-density lipoprotein (LDL) levels 
in HIV+ve patients on ART relative to ART naïve patients (6). Elevated circulating LDL cholesterol 
(LDL-c) contributes to several of the metabolic syndrome like symptoms observed in people on ART. 
Despite established prevalence of metabolic syndrome and altered cholesterol homeostasis in this 
population, there is a dearth of knowledge on gallstone disease, a disease closely linked to both these 
factors (10). 
Cholesterol gallstones, the result of biliary cholesterol superseding it saturation point causing 
cholesterol microcrystal formation (11), account for ~80% of all gallstones in western populations (12). 
The aetiology of gallstone formation involves an interplay between genetic and environmental factors. 
Risk factors include obesity, female sex, high oestrogen levels, aging, diabetes and metabolic syndrome 
(13,14). Historically, gallstone disease was most prevalent in North America, South America, some 
European populations and India (15); however, the rapid rate of urbanization, high fat diets and the 
influence of HIV on non-communicable diseases has seen a paradigm shift, warranting more 
investigation into developing countries and Sub-Saharan Africa (14). Data collected in South Africa 
suggest a steady increase in gallstone disease in Black African people over the past ten years (16,17). 
Considering the HIV endemic setting, very little is known on HIV+ve patients on ART with gallstone 
disease (18).  
Gallstones are the result of a shift in equilibrium of the triad of cholesterol, bile acid and lecithin, 
favouring bile to exist in a lithogenic state rather than liquid state (11). Bile acid synthesis is initiated 
by the rate limiting enzyme cholesterol 7-alpha hydroxylase (CYP7A1), which catalyses the conversion 
of cholesterol to 7-alpha-hydroxycholesterol (19). The CYP7A1 enzyme is regulated via multiple 
pathways including a negative feedback loop from the hepato-enteric circulation of bile acids (20). As 
CYP7A1 regulates the first step of bile acid synthesis, it has been extensively investigated in relation 
to gallstone formation. Several studies have evaluated genetic variations in the CYP7A1 gene in relation 
to gallstone disease risk with stronger links found to genetic predisposition in males compared to 
89 
 
females (21–24), while a deficiency in the enzyme is associated with gallstone formation (25,26). 
Considering that women are disproportionately affected by gallstone disease and the demographic at 
highest risk for new HIV infections in South Africa, alternative molecular mechanisms need to be 
investigated. 
The transcription of the CYP7A1 gene is regulated by transcription factors in response to fluctuations 
in bile acid and cholesterol. Hepatocyte nuclear factors (HNFs) are a group of transcription factors 
predominantly expressed in the liver that maintain metabolic homeostasis through the regulation of 
genes involved in glucose, cholesterol and fatty acid metabolism (27). Hepatocyte nuclear factor 1 alpha 
(HNF1α) and hepatocyte nuclear factor 4 alpha (HNF4α) are HNFs that respond to bile acid levels: 
HNF4α binds directly to CYP7A1 (28) while HNF1α binds to CYP7A1 regulators - hepatic bile acid 
binding protein and Farnesoid X receptor (FXR) (29). MicroRNAs (miRNAs), namely miR-194-5p and 
miR-122*_1 is chiefly regulated by HNF4α in the liver (30,31). Liver X receptor α/β (LXR α/β) is 
closely related to FXRs and binds to the liver x receptor element (LXRE) of LXR target genes. Among 
these target genes are regulators of reverse cholesterol transport, the most prominent being ATP-binding 
cassette (ABC-) G1, ABCG5 and ABCG8. The activity of these cellular efflux pumps determines 
cholesterol flux, thus regulating CYP7A1 activity in response to hepatic cholesterol concentration 
(32,33).   
Nuclear factors like HNFs and LXRs are key upstream regulators of hepatic cholesterol metabolism 
and bile acid synthesis. Dysregulation of these transcriptional regulators leads to pathogenic outcomes 
that underlie metabolic disorders. This present study sought to evaluate the expression of hepatic 
nuclear factors (HNF1α, HNF4α and LXRb) and miRNAs (HNF4α specific: miR-194-5p and miR-
122*_1) that regulate CYP7A1 transcription in HIV+ve Black South African women on ART and 
presenting with gallstones relative to HIV-ve women with gallstone disease.  
METHODS 
Patient recruitment 
This study utilized a case-series design comparing hepatic expression of cholesterol regulating genes in 
HIV+ve and HIV-ve women presenting with symptomatic gallstones. Ethical approval was obtained 
from the University of KwaZulu Natal (UKZN) Biomedical Research Ethics Committee (BREC) 
(BE276/16). Patients undergoing cholecystectomy for gallstone disease (biliary cholic, cholecystitis, 
jaundice and gall stone pancreatitis) at King Edward VIII Hospital, Durban, KwaZulu-Natal, South 
Africa from January – December 2017 were recruited. In total 52 Black South African women gave 
informed consent (standard consent form in two official main languages, i.e., English and isiZulu) for 
retrieval of a liver biopsy and recording of clinical parameters of patients including age, race, BMI, 
family history of gall stones and comorbidities (HIV, hypertension, diabetes, hypercholesterolemia).  
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Following the analysis of clinical parameters in all subjects, five HIV-ve and five HIV+ve women were 
selected for mRNA analysis to identify hepatic nuclear factors that were differentially regulated. All 
patients selected were of Black African ethnicity and female with no co-morbidities (diabetes and 
hypertensive statin therapy). All HIV+ve patients were on fixed dose combination (FDC) therapy with 
CD4 counts above 500 cells/mm3 and undetectable viral loads. FDC regimen consisted of 3 drugs 
namely; two Nucleoside reverse transcriptase inhibitors (NRTIs) drugs [Tenofovir Disoproxil Fumarate 
(TDF) and Emtricitabine (FTC) and one Non-nucleoside reverse transcriptase inhibitor (NNRTI) 
[Efavirenz (EFV)]. Common second line agents used were Protease inhibitors (PI) [Lopinivar/ritonavir 
(Aluvia) or Atazanavir/ritonavir]. None of the patients were on Integrase strand transfer inhibitor 
(InSTI) [Dolutegravir (DTG)] based therapies.  
RNA extraction and Real Time Quantitative PCR (RT-qPCR) 
Liver tissue (1cm x 1cm) was submerged in RNAlater® Stabilization Reagent (Qiagen) in 2ml cryovials 
at collection and stored at -80ºC until RNA isolation. RNA was extracted using a chloroform-based 
method using Qiazol lysis buffer (Qiagen) as per the manufacturer’s instructions. The purity and 
concentration of the crude RNA was assessed using the Nanodrop 2000 spectrophotometer (Thermo 
Fisher Scientific). The crude RNA was standardised to a concentration of 1,000ng/μl and stored at -
800C until further use. 
Thereafter, 1µg of the standardised RNA sample was used for complementary DNA (cDNA) synthesis 
using PCR. The miScript RT II kit (Qiagen) (miRNA gene expression studies) and QuantiTect Reverse 
Transcription kit (Qiagen) (gene expression studies) was used to make cDNA as per the manufacturer’s 
instructions. 
Messenger RNA quantification (CYP7A1, HNF1α, HNF4α and LXRb) and miRNA quantification (miR-
194-5p and miR-122*_1) was performed using the Applied Biosystems Viia7 Real-Time PCR System 
(Thermo Fisher Scientific).  
MiRNA expression studies was performed using the miScriptTM SYBRTM Green PCR kit (Qiagen, 
Hilden, Germany) and specific miScript Primer Assays for the above-mentioned miRNAs (Qiagen) 
according to the manufacturer’s instructions. Human RNA, U6 small nuclear 2 (RNU6-2) was used as 
a housekeeping gene.  
Messenger RNA gene expression studies was performed using the PowerUp™ SYBR™ Green Master 
Mix (Thermo Fisher Scientific) and specifically designed primer sequences for the above-mentioned 
genes (Inqaba Biotec) according to the manufacturer’s instructions. The sense and antisense primer 
sequences for the above-mentioned genes are shown in Table 1 together with their annealing 
temperature. Housekeeping genes GAPDH and 18SrRNA were concurrently quantified for 
normalization of results.  
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TABLE 4. 1: Primer sequences and annealing temperatures for RT-qPCR 





5’- ACCAAGCCGGTCTTCCATACT -3’ 




5’- CACGGGCAAACACTACGGT -3’ 




5’- AGAAGATTCGGAAACAACAGCA -3’ 




5’- GAGAAGGCAAACGGGTGAAC -3’ 




Comparisons of clinical parameters between HIV-ve and HIV+ve women presenting with gall stones 
were done by performing a Mann-Whitney U Test. All data were analysed using the GraphPad Prism 7 
statistical software package. A p<0.05 were considered statistically significant. 
RT-qPCR analysis of mRNA levels was performed using the QuantStudio 7 Pro Real-Time PCR 
Systems Software (Thermo Fisher Scientific). Messenger RNA and miRNA levels were reported as 




Clinical characteristics of patients 
Analysis of clinical parameters are summarized in Table 2. The HIV+ve group was significantly older 
than the HIV-ve group (p = 0.0267). The results show that the HIV+ve group had a lower BMI with 
overall higher levels of total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-c) and 








TABLE 4. 2: Clinical parameters of patients presenting with gall stones stratified based on HIV 
status 
Parameters HIV-ve HIV+ve p-value 
Age (years) 29.60±5.41 
  
39.60±6.189 *0.0267 
BMI (kg/m2) 34.06±5.980 32.63±10.84 0.807 
Total Cholesterol 
(mmol/L) 
3.640±1.107 4.882±0.9883 0.0986 
 Triglycerides (mmol/L) 0.7640±0.3886 0.8980±0.4909 0.6457 
HDL-c (mmol/L) 1.192±0.2821 1.328±0.5758 0.6526 
LDL-c (mmol/L) 2.096±0.7410 3.160±0.6403 *0.0419 
 
Hepatic CYP7A1, LXRb, HNF1α and HNF4α gene expression 
RT-qPCR analysis showed that hepatic mRNA levels of CYP7A1 were significantly higher in women 
with HIV and gallstone disease relative to women with gallstone disease alone [2.078-fold (RQ min: 
1.278; RQ max: 3.381)] (Figure 1). Transcriptional regulators of CYP7A1 were subsequently quantified: 
LXRb [2.595-fold (RQ min: 2.001; RQ max: 3.000)] (Figure 2A) and HNF1a [3.428-fold (RQ min: 
1.806; RQ max: 6.507] (Figure 2B) mRNA levels were concomitantly higher in the HIV+ve women 
compared to the HIV-ve group. Hepatic HNF4a mRNA levels were lower in HIV+ve women [0.642-





































Figure 4. 2: CYP7A1 regulators LXRb (A) and HNF1α (B) mRNA levels were significantly 
higher in HIV positive patients with gallstone disease (>2-fold). Hepatic HNF4α mRNA levels 
were lower in HIV infected women. 
 
Hepatic miR-194-5p and miR-122*_1 gene expression 
Hepatic miRNAs regulated by HNF4α were quantified by RT-qPCR. Both miR-194-5p [0.527-fold 
(RQ min: 0.37; RQ max: 0.752)] (Figure 3A) and miR-122*_1 [0.595-fold (RQ min: 0.332; RQ max: 
1.066)] (Figure 3B) were observed at lower concentrations in HIV+ve women with gallstone disease 
compared to HIV-ve women. 
 
Figure 4. 3: Hepatic expression of both miR-194-5p and miR-122*_1 was lower in 






DISCUSSION      
Gallstone disease is triggered by several risk factors, including female sex, aging, obesity, high 
oestrogen levels and dyslipidaemia (13, 14). Within the context of an African population, age, waist 
circumference and LDL-c were risk factors for gallstone disease in Sudanese individuals (34). In Black 
South African women, BMI and continuous exposure to a western lifestyle (characterised by high fat 
intake and low dietary fibre intake) were the main risk factors for gallstone disease (16).   
Long term use of ART has been linked to a number of metabolic diseases, however, there is a paucity 
of data on their association with gallstone disease in black South Africans (9–12). It has been 
demonstrated in other populations that the accumulative exposure to atazanavir/ritonavir for over 2 
years is associated with a 6.29-fold increase in the risk for incident cholelithiasis (38), whilst other 
studies report an increased rate of cholelithiasis (9,8%) in HIV+ve patients on protease inhibitor (PI)-
inclusive ART (39). HIV-infected patients on ART are more susceptible to hypercholesterolemia (6, 9). 
Despite newer integrase inhibitor (II) antiretroviral drugs showing lower lipid abnormalities than 
previously used PI-based ART, abnormalities in lipid concentration still occur, and this may be 
reflective either of the viral effects itself, chronic ART use or persistent immune activation in HIV 
infection (40).  
Atazanavir, ritonavir and indinavir significantly decreased CYP7A1 mRNA levels in rodent 
hepatocytes, indicating an effect of ART on the bile acid synthesis pathway (41,42). A substantial 
amount of evidence dating back as far as 1975 (43), together with more recent evidence have 
demonstrated that a deficiency in CYP7A1 (44), genetic variations in the CYP7A1 gene (45), and 
inhibition of CYP7A1 with lipid lowering drugs like fibrates (46), result in increased cholesterol 
excretion in bile which increases the risk of gallstone formation (22,26). Relative to Admirand’s theory, 
lower CYP7A1 activity compromises the conversion of cholesterol to bile acid resulting in increased 
cholesterol excretion and decreased bile acid excretion favoring gallstone formation (11). In Chilean 
Hispanic and Mapuche subjects (known to have one of the highest incidences of gallstones worldwide), 
an increase in CYP7A1 expression (47) and an increase in bile acid excretion (48) resulted in higher 
incidence of gallstone formation. Our study showed that HIV+ve women on ART displayed higher 
hepatic CYP7A1 mRNA (Figure 1), suggesting a possible response to impaired enterohepatic circulation 
of bile acids in HIV+ve women (49).  This finding warranted investigation into transcriptional 
regulators of CYP7A1 namely HNF1α, HNF4α and LXRb.    
The regulation of CYP7A1 by HNF1α has been studied extensively in mice, and found to downregulate 
CYP7A1 indirectly by binding to FXR receptors (29,50). In a murine study, HNF1α was found to be a 
transcriptional regulator of FXR, and when HNF1α was inhibited it resulted in downregulation of FXR 
with resultant gallstone formation (51). Moschetta et al. (2004) reported that FXR knockout mice that 
were fed a lithogenic diet displayed an increased susceptibility to developing gallstones. Administration 
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of the FXR agonist to the gallstone-susceptible mice decreased the susceptibility to gallstone formation 
(52). Similar findings were reported elsewhere that FXR upregulation decreased gallstone formation in 
mice (53). However, in a study by Chen et al. (1999) they demonstrated that unlike rodents where 
HNF1α regulates CYP7A1 by binding to FXR, in humans HNF1α binds directly to CYP7A1 and 
increases its transcriptional activity thus having the opposite effect to that in rodents (54). Similar to the 
findings from Chen et al. (1999), in our study HIV+ve women with gallstones displayed increased 
expression of CYP7A1 and HNF1α compared to their HIV-ve counterparts with gallstones, indicating 
that HIV may have an effect on HNF1α and CYP7A1.    
Another hepatic nuclear factor, HNF4α, binds directly to CYP7A1. Bile acids cause a negative feedback 
loop, resulting in down regulation of CYP7A1 not only via HNF1α and FXR but also HNF4α, which 
has a direct binding site on CYP7A1. Normally HNF4α binds and upregulates CYP7A1, however there 
is evidence that bile acids can downregulate CYP7A1 transcription by reducing the transactivation 
potential of HNF4α (28). In our findings however amongst HIV+ve women with gallstones, HNF4α 
was reduced in comparison to HIV-ve women, yet CYP7A1 was upregulated. This demonstrates that 
HNF4α on its own is not a regulator of CYP7A1 in the pathogenesis of gallstones in HIV+ve women. 
This mirrors other studies that demonstrated that HNF4α together with LRH-1, COUP, TFII and PCG-
1α are required for upregulation of CYP7A1. HNF4α on its own is not capable of this (55,56). Bacterial 
endotoxins, pro inflammatory cytokines (57), TNF-α and interleukin-1 produced by macrophages in the 
liver (58) are known to decrease the activity of CYP7A1. De Fabiani et al. (2001) demonstrated that 
HNF4α is the target transcriptional factor mediating the effects of these pro inflammatory cytokines on 
CYP7A1 (28). HIV+ve patients undergo a phenomenon of persistent inflammatory response which may 
account for the decrease in HNF4α levels (59).   
 
HNF4α is a key regulator of hepatic microRNAs miR-122 and miR-194. MiR-122 is found in 
abundance in the liver and plays an important role in regulating metabolic pathways including fatty acid 
synthesis and cholesterol biosynthesis (31). MiR-194 play a key role in hepatic cell functions (30). In 
our study, HNF4α expression was lower in the HIV-infected group which correlated with the decreased 
expression of miR-194-5p and miR-122*_1. This suggests that HNF4α may have more of an impact on 
microRNA expression in the liver that the CYP7A1 mediated bile acid synthesis pathway. 
LXR agonists have been shown to bind to LXRE on mouse CYP7A1 causing its upregulation (60). 
LXRE binds both LXRa and LXRb however LXRa binds stronger than LXRb thus LXRa knock out 
mice exhibit more cholesterol accumulation. However human CYP7A1 does not contain LXRE and is 
thus shown not to be upregulated by LXRa agonists and seems to be more affected by diet induced 
hypercholesterolemia due to its inability to convert cholesterol into bile salts (61). Goodwin et al. (2003) 
demonstrated a downregulation of CYP7A1 by LXR in response to cholesterol loading (62). Again, 
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there is implication that regulation of the entero-hepatic circulation may be a result of this as the 
compensation mechanism to decrease cholesterol absorption (by decreasing bile acid production) 
following a high cholesterol diet however in humans this compensatory mechanism has been shown to 
be inefficient (63).  In our study, the findings are in keeping with that of mice studies where LXRb 
increase co-existed with an upregulation of CYP7A1, indicating that LXRb might well be a regulator 
of CYP7A1 and gallstone formation in these group of patients compared to HIV-ve women with 
gallstones. Again, this may be due to underlying dysfunction of enterohepatic terminal ileum absorption 
in HIV+ve patients causing LXRb to increase CYP7A1 in an attempt to produce more bile acid for 
absorption (64).  
 
CONCLUSION   
In summary, HIV+ve women with gallstone disease displayed higher LDL-c levels and increased bile 
acid synthesis which was evident by the elevated expression of CYP7A1, HNF1α and LXRb. This could 
have been further influenced by ART and aging. HNF4α, which is known to cause upregulation of 
CYP7A1, was supressed with upregulation of CYP7A1 and LXR, known to cause downregulation of 
CYP7A1 in humans as opposed to mice, also had the opposite effect in HIV-infected women.  
The best theoretical explanation for this will be an interruption in the enterohepatic circulation, as 
evident by HIV+ve patients known to have chronic inflammatory and relative malabsorptive disorders 
of the ileum, which may result in upregulation of CYP7A1 to produce more bile salts. This is the most 
probable explanation for gallstone formation in HIV+ve patients, however will have to be validated 
with further trials and bigger sample size. 
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CHAPTER 5: SYNTHESIS, SUMMARY, CONCLUSION AND RECOMMENDATIONS 
This chapter presents a summary of the research findings, and assesses the strengths and limitations of 
this study. It also presents the conclusions, recommendations for improvement of existing management 
and offers suggestions for further research. 
 
5.1 Background 
The main aim of this study was to determine differences in clinical profiles and regulators of hepatic 
cholesterol and bile acid metabolism in HIV positive Black South African women on ART with GD 
compared to HIV negative Black South African women with GD. The significance of this study cannot 
be denied for several reasons; the incidence of HIV is highest amongst Black South African women 
particularly in KZN (1), the incidence of GD amongst Black South African women in the country is 
increasing (2,3), GD ranks as one of the world’s most expensive diseases (4), and ART is associated 
with lipid abnormalities which is the major driver for GD (5). The upsurge of GD in women of this 
population group living with HIV together with the impact of this high burden of GD on an already 
overstrained health system therefore gains importance and relevance by demonstrating possible links in 
order to identify research gaps and suggest novel ideas for future research. The findings will unravel 
areas where research is lacking as well as indicate possible preventative measures for developing GD 
and domains in clinical practice that need improvement or refinement to manage these patients with 
GD. Ultimately, the conclusions drawn will benefit the millions living with HIV in SA particularly 
those with GD.  
 
5.2 Key Findings of the Study 
The formation of cholesterol gallstones is complex and usually involves a combination of genetic and 
a host of environmental factors including lifestyle. Most research into the actual cause and risk factors 
of gallstones are performed in the West and parts of Europe with a paucity of data in any part of Africa 
due the lower incidence compared to the rest of the world (6). Whilst Black South Africans are now 
being exposed to most known risks such as urbanized diets and obesity (7), it not surprising that the 
patients in this study presenting with GD, show clear risks that are linked to those in the Western world 
in a disease that is rife amongst Caucasians. However, what is unknown is whether these risks apply to 
our HIV+ve population. From these observations, these patients do not conform entirely to the normal 
known risk profile. Black South African HIV+ve women with symptomatic gallstones were 
significantly younger. Black South African HIV-ve women conform to the known risk factor of obesity 
with a statically higher BMI whilst HIV+ve women do not.  HIV+ve women also had fewer 1st degree 
relatives with GD compared to HIV-ve women, and less oestrogen exposure. 
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Cholesterol homeostasis is complex, and dysregulation of the regulatory processes involved can lead to 
cholesterol gallstone formation. The impact of a chronic infectious disease, like HIV, needs to be 
considered in the context of rising incidence of metabolic disorders in developing countries.  
LDL-c is cholesterol that is available for delivery and cellular uptake; the circulating concentration is 
linked directly to dietary cholesterol consumption and associated with both cardiovascular disease and 
cholesterol gallstone formation (8). LDLr is shown to be directly regulated by miR-148a and is linked 
to gallstone formation in high fat diet fed mice (9) 
Our findings show a significant increase in circulating LDL-c in the HIV+ve group coupled with 
reduced mRNA expression of hepatic LDLr. However, the suppression of miR-148, an epigenetic 
regulator of LDLr, was downregulated in the HIV+ve group. This would indicate a possible alternate 
pathway in the downregulation of LDLr in HIV positive patients linked with raised LDL-c and gallstone 
formation and will require further investigation. MiR-148a however did appear to regulate ABCA1 with 
an inverse relationship being observed in the HIV positive patients. 
CYP7A1 is an enzyme involved in the rate limiting step of converting cholesterol to bile acid for 
excretion (10). When the cholesterol concentration within the hepatocyte is increased either by 
increased delivery to the liver or by increased production, CYP7A1 is activated via LXR to convert 
cholesterol into bile acid (11). 
HIV+ve women with gallstone disease displayed higher LDL-c levels and increased bile acid synthesis 
which was evident by the elevated expression of CYP7A1, HNF1α and LXRb. This could have been 
further influenced by ART and aging. HNF4α, which is known to cause upregulation of CYP7A1, was 
supressed with upregulation of CYP7A1 and LXR, known to cause downregulation of CYP7A1 in 
humans as opposed to mice, also had the opposite effect in HIV+ve women. The best theoretical 
explanation for this will be an interruption in the enterohepatic circulation, as evident by HIV+ve 
patients known to have chronic inflammatory and relative malabsorptive disorders of the ileum, which 
may result in upregulation of CYP7A1 to produce more bile salts.  
 
5.3 Strengths of the Study 
With the information gained from a case series, it has the advantage of being used to generate 
hypotheses that lead to focussed studies of a stronger designs. As our study of GD in HIV +ve patients 
was a first of any kind of study of this nature it will be helpful in refining new techniques or treatment 
protocols that can be studied in more advanced trials. Our study required less time and financial 
resources than case control, cohort studies or randomised-controlled trials. We believe that this case 
series was of high-quality as outlined by having several of the key criteria for a high-quality case series 
(12); clear study objective/question, well-defined study protocol, explicit inclusion and exclusion 
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criteria for study participants, specified time interval for patient recruitment, consecutive patient 
enrolment, clinically relevant outcomes, and a prospective outcome data collection (12).  
 
5.4 Limitations of the Study 
Overall, the study has made significant findings. Nonetheless, there are some limitations that must be 
acknowledged. Conclusions drawn from clinical profiles are from a case series rather than a case control 
setting. Case series represents an observational study that reports on data from a subject group without 
a comparison population. In the hierarchy of evidence, it represents level IV evidence (13,14). This is 
due to lack of control subjects, making case series prone to bias.  Most of the evidence of regulators of 
hepatic cholesterol and bile acid metabolism that have been compared to are from murine rather than 
human studies. Sample sizes were relatively small. Missing data despite not being small numbers could 
possibly influence the results obtained.  
 
5.5 Conclusions 
This study demonstrates the current stance of GD amongst Black South African women living with 
HIV in the era of ART. It also illustrates the importance of the deficiencies in knowledge and their 
implications for the future. The findings of this study in this population group with HIV differs from 
the findings of that to other population groups and the same population group living without HIV. What 
this study demonstrated are key areas in the differences and possible plausible causes at a cellular level, 
however will require much more research to draw concrete conclusions. ART seems to be a mighty 
player in these differences as well, and the universal access to ART for all HIV-infected South Africans 
will likely result in an increase in GD amongst other diseases. Thus, this implies that GD as a possible 
side effect of ART should be investigated with better emphasis as well especially if the incidence and 
prevalence amongst HIV+ve patients with GD is high. The impact on the current health infrastructure 
that this increasing disease will have is unknown. There is shortfall in the knowledge and statistics on 
the incidence and prevalence of GD in general and amongst those living with HIV with and without 
ART. There is thus a deficiency in evidence on the morbidity and mortality of HIV-infected patients 
with GD as well. More studies are required into the effects of HIV on GD and the impact of ART on 
GD in order to put strategies in place to curb this disease process and reduce the morbidity from it and 






Based on the study conclusions, the following recommendations are suggested: 
1. GD registries should be established which will assist the much-needed statistics on the 
morbidity and mortality of both HIV-related and non-related GD as well the ART effects.  
2. Larger studies be undertaken to validate the findings of this study that HIV+ve patients 
indeed have different risk profiles and pathophysiology’s to the development of GD 
3. The effect of ART specifically on gallstones formation needs to be studied.  
 
5.7 Future Studies 
Based on the study findings, the following areas of research are recommended: 
1. Larger population-based Cohort studies using patients without GD as a control and compare 
them to HIV+ve and HIV-ve patients with GD. 
2. The effect of abdominal fat and waist circumference vs BMI in HIV+ve patients as a risk factor 
for gallstone disease.  
3. Cohort studies looking at the baseline ultrasounds in those patients without gallstones upon 
ART initiation and following up the presence or absence of GD with time.  
4. Close monitoring of newer DTG drug initiation and the link of weight gain and GD. 
5. Studies looking at alternate pathways in evaluating the downregulation of LDL-r in HIV +ve 
patients. 
6. Entero-hepatic circulation and the effect on CYP7A1 to validate if there is a relative 













1.  South SMES. Africa: Statistical release P0302 Mid-year estimates.(various years) URL: 
http://www. statssa. gov. za/Local copy: http://www. hst. org. za/indicators. StatsSA;  
2.  Parekh D, Lawson HH, Kuyl JM. Gallstone disease among black South Africans. S Afr Med J. 
1987;72:23–6.  
3.  Khan ZA, Khan MU, Brand M. Increases in cholecystectomy for gallstone related disease in 
South Africa. Sci Rep. 2020;10(1):1–5.  
4.  Myer PA, Mannalithara A, Singh G, Singh G, Pasricha PJ, Ladabaum U. Clinical and economic 
burden of emergency department visits due to gastrointestinal diseases in the United States. Am 
J Gastroenterol. 2013;108(9):1496–507.  
5.  Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in 
man. J Clin Invest. 1968;47(5):1043–52.  
6.  Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin. 
2010;39(2):157–69.  
7.  Micklesfield LK, Lambert E V, Hume DJ, Chantler S, Pienaar PR, Dickie K, et al. Socio-
cultural, environmental and behavioural determinants of obesity in black South African women. 
Cardiovasc J Afr. 2013;24(9):369.  
8.  Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low 
density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 
1993;34(10):1637–59.  
9.  Wagschal A, Najafi-Shoushtari SH, Wang L, Goedeke L, Sinha S, Andrew S deLemos, et al. 
Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. 
Nat Med. 2015;21(11):1290–7.  
10.  Miao J. Regulation of bile acid biosynthesis by orphan nuclear receptor small heterodimer 
partner. University of Illinois at Urbana-Champaign; 2008.  
11.  Chawla A, Saez E, Evans RM. Don’t know much bile-ology. Cell. 2000;103(1):1–4.  
12.  Chan K, Bhandari M. Three-minute critical appraisal of a case series article. Indian J Orthop. 
2011;45(2):103–4.  
13.  Degen RM, Hodgins JL, Bhandari M. The language of evidence based medicine: answers to 
common questions? Indian J Orthop. 2008;42(2):111.  
14.  Bhandari M, Joensson A. Clinical research for surgeons. Thieme; 2011.  
108 
 
CHAPTER 6: ADDENDUMS 
6.1 Ethics Approval 
 
 
NOTE: Protocol name differs from title name of PhD study. Title reworded to better suit the protocol. 




6.2 Site Approval  
 
 
 
 
 
 
